10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________________________

FORM 10-Q

_____________________________________

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-11442

_____________________________________

CHART INDUSTRIES, INC.

(Exact Name of Registrant as Specified in its Charter)

_____________________________________

Delaware	34-1712937
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

One Infinity Corporate Centre Drive, Suite 300, Garfield Heights, Ohio 44125

(Address of Principal Executive Offices) (ZIP Code)

Registrant’s Telephone Number, Including Area Code: (440) 753-1490

NOT APPLICABLE

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

_____________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

At November 1, 2012, there were 30,015,307 outstanding shares of the Company’s Common Stock, par value $0.01 per share.

CHART INDUSTRIES, INC.

INDEX

Part I. Financial Information
Item 1. Financial Statements	Page
Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011	3
Condensed Consolidated Statements of Income and Comprehensive Income for the Three and Nine Months Ended September 30, 2012 and 2011	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011	5
Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3. Quantitative and Qualitative Disclosures About Market Risk	29
Item 4. Controls and Procedures	29
Part II. Other Information
Item 1A. Risk Factors	30
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 4. Mine Safety Disclosures	30
Item 5. Other Information	30
Item 6. Exhibits	30
Signatures	32

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands, except per share amounts)

	September 30, 2012		December 31, 2011
	(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents	$	105,775	$	256,861
Accounts receivable, less allowances of $4,402 and $2,360	181,170		131,904
Inventories, net	204,779		149,822
Unbilled contract revenue	25,462		25,247
Prepaid expenses	13,403		7,088
Deferred income taxes	29,323		14,004
Other current assets	11,959		12,703
Total Current Assets	571,871		597,629
Property, plant and equipment, net	158,672		137,301
Goodwill	387,242		288,770
Identifiable intangible assets, net	194,631		140,553
Other assets, net	10,820		10,222
TOTAL ASSETS	$	1,323,236	$	1,174,475
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable	$	85,416	$	84,297
Customer advances and billings in excess of contract revenue	106,438		102,996
Accrued salaries, wages and benefits	27,228		29,108
Current portion of warranty reserve	20,187		13,181
Short-term debt	23,157		4,758
Current portion of long-term debt	3,750		6,500
Other current liabilities	28,170		24,653
Total Current Liabilities	294,346		265,493
Long-term debt	250,640		223,224
Long-term deferred tax liability, net	68,425		43,945
Accrued pension liabilities	13,841		15,905
Other long-term liabilities	17,002		12,357
Equity
Chart Industries’ shareholders’ equity:
Common stock, par value $.01 per share – 150,000,000 shares authorized, 30,000,390 and 29,612,684 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	300		296
Additional paid-in capital	345,707		333,034
Retained earnings	325,251		274,716
Accumulated other comprehensive income	4,357		2,993
Total Chart Industries, Inc. shareholders’ equity	675,615		611,039
Noncontrolling interest	3,367		2,512
Total equity	678,982		613,551
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	1,323,236	$	1,174,475

The balance sheet at December 31, 2011 has been derived from the audited financial statements at that date, but does not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements.

See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED)

(Dollars and shares in thousands, except per share amounts)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2012		2011			2012		2011
Sales	$	254,249	$	211,311		$	710,294	$	574,950
Cost of sales	176,237		144,680			490,596		393,503
Gross profit	78,012		66,631			219,698		181,447
Selling, general and administrative expenses	42,170		34,127			117,522		105,326
Amortization expense	3,810		3,342			10,130		9,947
Impairment of intangible assets	—		—			3,070		—
Loss on disposal of assets	—		119			—		1,335
	45,980		37,588			130,722		116,608
Operating income	32,032		29,043			88,976		64,839
Other expenses (income):
Interest expense, net	4,006		6,361			11,657		14,358
Financing costs amortization	326		445			1,203		1,094
Foreign currency losses (gains)	461		(2,390		)	1,879		(2,533		)
	4,793		4,416			14,739		12,919
Income before income taxes	27,239		24,627			74,237		51,920
Income tax expense	8,354		7,122			23,064		15,992
Net income	18,885		17,505			51,173		35,928
Noncontrolling interest, net of tax	369		(35		)	638		267
Net income attributable to Chart Industries, Inc.	$	18,516	$	17,540		$	50,535	$	35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$	0.62	$	0.60		$	1.70	$	1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$	0.61	$	0.59		$	1.68	$	1.19
Weighted average number of common shares outstanding – basic	29,839		29,288			29,743		29,088
Weighted average number of common shares outstanding – diluted	30,243		29,966			30,168		29,871
Comprehensive income, net of tax	$	21,428	$	6,459		$	52,537	$	32,292
Less: Comprehensive income (loss) attributable to noncontrolling interest, net of tax	369		(35		)	638		267
Comprehensive income attributable to Chart Industries, Inc., net of tax	$	21,059	$	6,494		$	51,899	$	32,025

See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Dollars in thousands)

	Nine Months Ended September 30,
	2012			2011
OPERATING ACTIVITIES
Net income	$	51,173		$	35,928
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,771			20,410
Interest accretion of convertible notes discount	6,764			1,421
Employee share-based compensation expense	5,711			4,208
Financing costs amortization	1,203			1,094
Foreign currency losses (gains)	3,095			(1,559		)
Loss on disposal of assets	—			1,335
Impairment of intangible assets	3,070			—
Reversal of contingent consideration liability	(4,620		)	—
Other non-cash operating activities	(609		)	(1,826		)
(Decrease) increase in cash resulting from changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(28,417		)	(23,358		)
Inventory	(22,594		)	(21,283		)
Unbilled contract revenues and other current assets	(3,882		)	(10,244		)
Accounts payable and other current liabilities	(18,134		)	6,312
Customer advances and billings in excess of contract revenue	(1,058		)	24,605
Net Cash Provided By Operating Activities	14,473			37,043
INVESTING ACTIVITIES
Capital expenditures	(28,951		)	(15,161		)
Proceeds from sale of assets	2,040			—
Acquisition of businesses, net of cash acquired	(182,450		)	(37,680		)
Other investing activities	(359		)	388
Net Cash Used In Investing Activities	(209,720		)	(52,453		)
FINANCING ACTIVITIES
Proceeds from long-term debt	21,375			—
Borrowings on revolving credit facilities	18,387			—
Principal payments on long-term debt	(3,500		)	(4,875		)
Proceeds from issuance of convertible notes	—			250,000
Proceeds from issuance of warrants	—			48,848
Payment for call options related to convertible notes	—			(66,486		)
Payment of deferred financing costs	(1,445		)	(7,340		)
Proceeds from exercise of options	3,324			5,101
Tax benefit from exercise of stock options	7,934			6,984
Payment of contingent consideration	(1,300		)	(1,300		)
Common stock repurchases	(4,537		)	(1,090		)
Net Cash Provided By Financing Activities	40,238			229,842
Effect of exchange rate changes on cash	3,923			2,501
Net (decrease) increase in cash and cash equivalents	(151,086		)	216,933
Cash and cash equivalents at beginning of period	256,861			165,112
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	105,775		$	382,045

See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts)

NOTE A — Basis of Preparation

The accompanying unaudited condensed consolidated financial statements of Chart Industries, Inc. and its subsidiaries (the “Company” or “Chart”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for annual financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.

Principles of Consolidation: The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation. Investments in affiliates where the Company’s ownership is between 20 percent and 50 percent, or where the Company does not have control, but has the ability to exercise significant influence over operations or financial policy, are accounted for under the equity method.

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Reclassifications: Certain reclassifications have been made to the 2011 condensed consolidated balance sheet and condensed consolidated cash flow statement in order to conform to the 2012 presentation.

Nature of Operations: The Company is a leading global manufacturer of standard and custom-engineered products and systems serving a wide variety of low-temperature and cryogenic applications. The Company has developed an expertise in medical respiratory equipment and cryogenic systems and equipment, which operate at low temperatures sometimes approaching absolute zero. The majority of the Company’s products, including vacuum insulated containment vessels, heat exchangers, cold boxes and other cryogenic components, are used throughout the liquid-gas supply chain for the purification, liquefaction, distribution, storage and end-use of industrial gases and hydrocarbons. The Company has domestic operations located across the United States, including the principal executive offices located in Ohio, and an international presence in Asia, Australia and Europe.

Cost of Sales: Manufacturing expenses associated with sales are included in cost of sales. Cost of sales includes all materials, direct and indirect labor, inbound freight, purchasing and receiving, inspection, internal transfers and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs, manufacturing engineering, project management and depreciation expense for assets used in the manufacturing process are included in cost of sales.

Selling, General and Administrative Costs (SG&A): SG&A includes selling, marketing, customer service, product management, design engineering, and other administrative costs not directly supporting the manufacturing process as well as depreciation and amortization expense associated with non-manufacturing assets. In addition, SG&A includes corporate operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and share-based compensation expense.

Cash and Cash Equivalents: The Company considers all investments with an initial maturity of three months or less when purchased to be cash equivalents. The December 31, 2011 balances include money market investments, certificates of deposit, and commercial paper. As of September 30, 2012, Chart Cryogenic Distribution Equipment (Changzhou) Company Limited, a joint venture of the Company, and Chart Cryogenic Engineering Systems (Changzhou) Company Limited held $1,055 and $844 in restricted cash on deposit, respectively, to cover guarantees.

Short-Term Investments: From time to time, the Company invests in short-term, highly liquid, variable rate instruments, which have stated maturities of greater than three months but less than six months. These short-term investments are recorded at cost which approximates fair value. The Company has determined that its investment securities are available and intended for use in current operations and, accordingly, classifies investment securities as current assets. There were no short term investments at September 30, 2012 or December 31, 2011.

6

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

Inventories: Inventories are stated at the lower of cost or market with cost being determined by the first-in, first-out (“FIFO”) method. The components of inventory are as follows:

	September 30, 2012		December 31, 2011
Raw materials and supplies	$	84,686	$	64,832
Work in process	46,719		36,045
Finished goods	73,374		48,945
	$	204,779	$	149,822

Revenue Recognition: For the majority of the Company’s products, revenue is recognized when products are shipped, title has transferred and collection is reasonably assured. For these products, there is also persuasive evidence of an arrangement and the selling price to the buyer is fixed or determinable. For brazed aluminum heat exchangers, cold boxes, liquefied natural gas fueling stations and engineered tanks, the Company uses the percentage of completion method of accounting. Earned revenue is based on the percentage of incurred costs to date compared to total estimated costs at completion after giving effect to the most current estimates. The cumulative impact of revisions in total cost estimates during the progress of work is reflected in the period in which these changes become known. Earned revenue reflects the original contract price adjusted for agreed upon claims and change orders, if any. Losses expected to be incurred on contracts in process, after consideration of estimated minimum recoveries from claims and change orders, are charged to operations as soon as such losses are known. Pre-contract costs relate primarily to salaries and benefits incurred to support the selling effort and are expensed as incurred. Change orders resulting in additional revenue and profit are recognized upon approval by the customer based on the percentage of incurred costs to date compared to total estimated costs at completion. Certain contracts include incentive-fee arrangements. The incentive fees in such contracts can be based on a variety of factors but the most common are the achievement of target completion dates, target costs, and/or other performance criteria. Incentive-fee revenue is not recognized until it is earned. Timing of amounts billed on contracts varies from contract to contract and could cause a significant variation in working capital requirements. The Company reports sales net of tax assessed by qualifying governmental authorities.

Product Warranties: The Company provides product warranties with varying terms and durations for the majority of its products. The Company calculates its warranty reserve by considering historical warranty experience and specifically identified warranty issues. The Company records warranty expense in cost of sales. Product warranty claims not expected to occur within one year are recorded in other long-term liabilities in the condensed consolidated balance sheets. Actual experience could differ from the amounts estimated requiring adjustments to the liability in future periods. The changes in the Company’s consolidated warranty reserve during the three and nine months ended September 30, 2012 and 2011 are as follows (see Note G for further details on the acquired warranty reserves):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Beginning balance	$	11,248		$	12,849		$	13,181		$	13,372
Warranty expense	2,741			1,631			6,343			5,233
Warranty usage	(3,722		)	(1,949		)	(9,257		)	(6,074		)
Acquired warranty reserves	18,779			817			18,779			817
Ending balance	$	29,046		$	13,348		$	29,046		$	13,348

Goodwill and Other Intangible Assets: The Company does not amortize goodwill or other indefinite-lived intangible assets, but reviews them at least annually for impairment, and on an interim basis if necessary, using a measurement date of October 1st. The Company amortizes intangible assets that have finite lives over their useful lives.

With respect to goodwill, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The reporting units are the same as our operating segments, which are also the reportable segments: Energy & Chemicals, Distribution & Storage, and BioMedical. The Company first evaluates relevant events and circumstances, such as macroeconomic conditions and the Company's overall financial performance to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company then evaluates how significant each of the identified factors could be to the fair value or carrying amount of a reporting unit and weighs these factors in totality in forming a conclusion whether it is more likely than not that the fair value of a reporting unit

7

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, further goodwill impairment testing is not necessary. Otherwise, the Company would perform the first step of the two-step goodwill impairment test. As of October 1, 2011, and based on the Company's qualitative assessment, the Company determined that it was not more likely than not that the fair value was less than the carrying amount of each reporting unit and, therefore, the two-step goodwill impairment test was not necessary.

With respect to other indefinite-lived intangible assets, the Company determines the fair value of any indefinite-lived intangible asset using an income approach, compares the fair value to its carrying amount and records an impairment loss if the carrying amount exceeds its fair value. The Company uses the relief from royalty method to develop fair value estimates for trade names and trademarks. This method focuses on the level of royalty payments that the user of an intangible asset would be willing to pay for the use of the asset if it were not owned by the user. This method has been consistently applied between years. As of October 1, 2011, the Company determined that the fair values of trademarks, trade names, and in-process research and development exceeded their carrying amounts. For the nine months ended September 30, 2012, the Company recorded an impairment loss of $3,070 resulting in the elimination of in-process research & development (IPR&D) intangible assets related to a prior BioMedical segment acquisition. During the second quarter of 2012, higher forecasted costs and project delays represented impairment indicators requiring the Company to re-evaluate the fair value of the IPR&D intangible assets. The Company conducted an impairment test in accordance with Accounting Standards Codification (ASC) 350-30 "General Intangibles Other Than Goodwill" based on the multi-period excess earnings valuation method which determines fair value based on the present value of the prospective net cash flow attributable to the intangible asset. The Company determined that the fair value of the IPR&D intangible assets was zeroand impaired the intangible assets by a value equal to their carrying amount.

The following table displays the gross carrying amount and accumulated amortization for all intangible assets:

		September 30, 2012					December 31, 2011
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived assets:
Unpatented technology	9 years	$	41,461	$	(10,305	)	$	18,113	$	(9,024	)
Patents	10 years	8,980		(6,914		)	9,080		(5,434		)
Product names	14 years	9,281		(2,261		)	5,638		(1,818		)
Customer relations	13 years	165,192		(56,018		)	130,488		(48,840		)
		$	224,914	$	(75,498	)	$	163,319	$	(65,116	)
Indefinite-lived intangible assets:
Trademarks and trade names		$	45,215				$	39,280
In-process research and development		—					3,070
		$	45,215				$	42,350

The following table represents the changes in goodwill:

Balance as of January 1, 2012	$	288,770
Foreign currency adjustments	(177		)
Acquisition of AirSep Corporation	98,649
Balance as of September 30, 2012	$	387,242

8

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

Amortization expense for intangible assets subject to amortization was $3,810 and $3,342 for the three months ended September 30, 2012 and 2011, respectively, and $10,130 and $9,947 for the nine months ended September 30, 2012 and 2011. The Company estimates amortization expense to be recognized during the next five years as follows:

For the Year ending December 31,
2012	$	15,100
2013	18,900
2014	17,600
2015	15,900
2016	14,100

Share-based Compensation: The Company records share-based compensation to employees and directors, including grants of employee stock options, to be measured at fair value on the date of grant and expensed over the vesting period.

During the nine months ended September 30, 2012, the Company granted 104 stock options, 31 shares of restricted stock and stock unit awards, 15 performance stock units, and 18 leveraged restricted stock units. Non-employee directors received 4 stock awards with a fair value of $274. During the nine months ended September 30, 2012, participants in the Company's stock option plans exercised options to purchase 286 shares of the Company's common stock.

The stock options vest ratably over a four year period. Restricted stock and stock unit awards generally vest ratably over a three year period, and performance stock units and leveraged restricted stock units vest at the end of three years based on the achievement of certain performance and market conditions.

Share-based compensation expense was $1,530 and $1,407 for the three months ended September 30, 2012 and 2011, respectively, and $5,711 and $4,208 for nine months ended September 30, 2012 and 2011, respectively. As of September 30, 2012, the total share-based compensation expected to be recognized over the weighted average period of approximately 1.9 years is $8,075.

Convertible Debt: The Company determined that the embedded conversion feature within the Convertible Senior Subordinated Notes (the “Convertible Notes”) was clearly and closely related to the Company’s common stock and therefore exempt from separate accounting treatment under ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” Convertible Notes exempt from derivative accounting are recognized according to ASC 470-20, “Debt with Conversion and Other Options” by bifurcating the principal balance into a liability component and an equity component where the fair value of the liability component is estimated by calculating the present value of its cash flows discounted at an interest rate that the Company would have received for similar debt instruments that have no conversion rights (the “straight-debt rate”), and the equity component is the residual amount, net of tax, which creates a discount on the Convertible Notes. The Company recognizes non-cash interest accretion expense related to the carrying amount of the Convertible Notes which is accreted back to its principal amount over the expected life of the debt, which is also the stated life of the debt.

Recently Issued Accounting Pronouncements: In December 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-12, “Comprehensive Income – Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05 (Topic 220).” The amendments were made to allow the FASB time to consider whether there should be additional presentation and disclosure requirements for reclassifications out of accumulated other comprehensive income on the components of net income and other comprehensive income for all periods presented. All other requirements in ASU 2011-05 are not affected by this update. The adoption of this guidance did not have a material impact on the financial statements of the Company.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220).” The amendments in the ASU revise the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Topic 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. The amendments do not change the items that must be reported in other comprehensive income. The adoption of this guidance did not have a material impact on the financial statements of the Company since the amendments affect financial statement presentation only.

9

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

In May 2011, the FASB issued ASU 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (Topic 820).” The amendments in the ASU aim to align the principles for fair value measurements and the related disclosure requirements in accordance with U.S. GAAP and IFRS. This ASU mainly contains clarifications such as the specification that the "highest and best use" valuation concept for fair value measurements is relevant only when measuring the fair value of nonfinancial assets and is not relevant when measuring the fair value of financial assets or of liabilities. The ASU also requires new disclosures under U.S. GAAP such as quantitative information about the unobservable inputs used in a fair value measurement that is categorized within the Level 3 of the fair value hierarchy. The adoption of this guidance did not have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE B — Fair Value Measurements

The Company measures assets and liabilities at fair value on a recurring basis in three levels of input. The three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies, is:

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company is exposed to foreign currency exchange risk as a result of transactions in currencies other than the functional currency of certain subsidiaries. The Company utilizes foreign currency forward purchase and sale contracts to manage the volatility associated with foreign currency purchases and certain intercompany transactions in the normal course of business. Contracts typically have maturities of less than one year. Principal currencies include the euro, the British pound, the Czech koruna, the Japanese yen, and the Chinese yuan. The Company’s foreign currency forward contracts do not qualify as hedges as defined by accounting guidance. Changes in their fair value are recorded in the condensed consolidated statements of income and comprehensive income as foreign currency gains or losses. The changes in fair value generated net losses of $1,068 and $1,379 for the three months ended September 30, 2012 and 2011, respectively, and a net loss and a net gain of $1,619 and $1,943 for the nine months ended September 30, 2012 and 2011, respectively.

As of September 30, 2012, the Company held forward currency contracts to sell (in thousands): (i) 48,700 euros against the U.S. dollar, (ii) 2,280 euros against the Czech koruna, (iii) 800 Australian dollars against the U.S. dollar, (iv) 60,000 Japanese yen against the U.S. dollar, (v) 700 British pounds against the U.S. dollar, (vi) 510 British pounds against the Czech koruna, (vii) 980 U.S. dollars against the Czech koruna, and (viii) 200 British pounds against the euro. As of September 30, 2012, the fair value of the Company’s derivative assets and liabilities representing foreign currency forward contracts was $11 and $1,655, respectively, and were recorded in the condensed consolidated balance sheet as other current assets and liabilities.

As of December 31, 2011, the Company held forward currency contracts to buy 17,500 Czech koruna against the euro and to sell (i) 11,500 euros against the U.S. dollar, (ii) 4,700 Czech koruna against the U.S. Dollar, (iii) 130,000 Japanese yen against the U.S. dollar, (iv) 3,340 euros against the Czech koruna, (v) 3,000 Norwegian kroner against the euro, and (vi) 250 British pounds against the U.S. dollar. As of December 31, 2011, the fair value of the Company’s derivative assets and liabilities representing foreign currency forward contracts was $489 and $191, respectively. These were recorded in the condensed consolidated balance sheet as other current assets and liabilities. The Company’s foreign currency forward contracts are not exchange traded instruments and, accordingly, are classified as being valued using Level 2 inputs which are based on observable inputs such as quoted prices for similar assets and liabilities in active markets.

The Company does not enter into derivative instruments for trading or speculative purposes.

The fair value of the Company’s term loan portions of both the Restated Credit Facility (Term Loan) and the former Senior Credit Facility (as defined in Note C below) is estimated based on the present value of the underlying cash flows discounted using market interest rates. Under this method, the fair value of the Company’s Term Loan approximated its carrying amount as of September 30, 2012, and the fair value of the former Senior Credit Facility approximated its carrying amount as of December 31, 2011. The Company’s Term Loan and former Senior Credit Facility were valued using observable inputs and, accordingly, are classified as being valued using Level 2 inputs.

10

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

The fair value of the Convertible Notes exceeded its carrying amount by approximately 131% as of September 30, 2012 and approximately 108% as of December 31, 2011. The Convertible Notes are actively quoted instruments and, accordingly, are classified as being valued using Level 1 inputs. The fair value of the liability component of the Convertible Notes is based on the present value of its associated cash flows using a market interest rate for similar debt instruments without a conversion feature. The liability component of the Convertible Notes uses observable inputs other than quoted prices for similar liabilities in active markets and, accordingly, is classified as being valued using Level 2 inputs.

The estimated fair value of total contingent consideration relating to acquisitions in prior years as of September 30, 2012 and December 31, 2011 was $1,990 and $7,067, respectively, and was valued using a discounted cash flow approach, which includes assumptions for the probabilities of achieving gross sales or gross profit targets and the discount rate applied to the projected payments. The increase in fair value of total contingent consideration for the three months ended September 30, 2012 included increases of $73 and $15 related to prior BioMedical and Distribution & Storage acquisitions, respectively. The decrease in fair value of total contingent consideration for the nine months ended September 30, 2012 of $5,077 included a decrease of $4,236 related to a prior BioMedical acquisition offset by an increase of $459 related to a prior Distribution & Storage acquisition. There was also a $1,300 payment related to a prior Distribution & Storage acquisition during the nine months ended September 30, 2012. The majority of the decrease in fair value was caused by an adjustment to a contingent consideration obligation related to a prior BioMedical segment acquisition as a result of higher forecasted costs and delays of certain BioMedical projects. As noted in the Goodwill and Other Intangible Assets paragraph in Note A above, the Company determined that it would no longer meet the forecasted gross profit target required to satisfy its contingent consideration obligation. Therefore, the fair value of the contingent consideration obligation was determined to be zero.

The changes in fair value of contingent consideration were recorded as selling, general and administrative expenses in the condensed consolidated statements of income and comprehensive income. Based on achieving gross sales targets, the remaining maximum potential payout related to another prior BioMedical acquisition is $3,000. The valuation of contingent consideration is valued utilizing Level 3 inputs with reasonably available assumptions consistent with those made by other market participants.

NOTE C — Debt and Credit Arrangements

In August 2011, the Company issued Convertible Notes in the aggregate principal amount of $250,000 in an offering registered under the Securities Act of 1933, as amended. The net proceeds from the offering were approximately $242,700 after deducting the underwriters’ discount and offering expenses. The Convertible Notes bear interest at a fixed rate of 2.00% per year, payable semiannually in arrears on February 1 and August 1 of each year which began on February 1, 2012. The Convertible Notes mature on August 1, 2018.

The Convertible Notes are senior subordinated unsecured obligations of the Company and are not guaranteed by any of the Company’s subsidiaries. The Convertible Notes are subordinated in right of payment to the Company’s existing and future senior indebtedness, including indebtedness under the Company’s existing credit agreement, and rank equally in right of payment with any future senior subordinated debt. The Convertible Notes rank senior in right of payment to the Company’s future subordinated debt.

Prior to May 1, 2018, the Convertible Notes will be convertible at the option of the holders thereof only under the following circumstances: (1) during any fiscal quarter commencing after September 30, 2011 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price for the Convertible Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “Measurement Period”) in which, as determined following a request by a holder of Convertible Notes as provided in the bond indenture (the “Indenture”), the trading price per $1,000 principal amount of Convertible Notes for each trading day of such Measurement Period was less than 97% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate for the Convertible Notes on each such trading day; or (3) upon the occurrence of specified corporate events pursuant to the terms of the Indenture. On or after May 1, 2018, until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders of the Convertible Notes may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, in respect of the remainder, if

11

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted. It is the Company’s intention to settle any excess conversion value in shares of the Company’s common stock.

The conversion rate will initially equal 14.4865 shares of the Company’s common stock per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $69.03 per share. The conversion rate will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of a make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate for a holder that converts its Convertible Notes in connection with such make-whole fundamental change. The Company may not redeem the Convertible Notes prior to maturity. No sinking fund will be provided for the Convertible Notes. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to purchase

the Convertible Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the Convertible Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. In certain Events of Default, as defined in the Indenture, the Trustee by notice to the Company, or the holders of at least 25% in principal amount of then outstanding Convertible Notes by notice to the Company and to the Trustee, may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all then outstanding Convertible Notes to be due and payable. Upon such a declaration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

As of September 30, 2012, the Convertible Notes were not subject to conversion.

In connection with the issuance of the Convertible Notes, the Company entered into privately-negotiated convertible note hedge and capped call transactions with affiliates of certain of the underwriters (the “Option Counterparties”). The convertible note hedge and capped call transactions relate to, collectively, 3,622 shares, which represents the number of shares of the Company’s common stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes. These convertible note hedge and capped call transactions are expected to reduce the potential dilution with respect to the Company’s common stock upon conversion of the Convertible Notes and/or reduce the Company’s exposure to potential cash or stock payments that may be required upon conversion of the Convertible Notes, except, in the case of the capped call transactions, to the extent that the market price per share of the Company’s common stock exceeds the cap price of the capped call transactions. The convertible note hedge and capped call transactions, which cost the Company $66,486, were recorded as a reduction of additional paid-in-capital.

The Company also entered into separate warrant transactions with the Option Counterparties initially relating to the number of shares of the Company’s common stock underlying the convertible note hedge transactions, subject to customary anti-dilution adjustments. The warrant transactions will have a dilutive effect with respect to the Company’s common stock to the extent that the price per share of the Company common stock exceeds the strike price of the warrants unless the Company elects, subject to certain conditions, to settle the warrants in cash. These warrants were exercisable as of the issuance date of the Convertible Notes. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. Proceeds received from the issuance of the warrants totaled approximately $48,848 and were recorded as an addition to additional paid-in-capital. The net cost of the convertible note hedge and capped call transactions, taking into account the proceeds from the issuance of the warrants, was approximately $17,638. In accordance with ASC 815, contracts are initially classified as equity if (1) the contract requires physical settlement or net-share settlement, or (2) the contract gives the entity a choice of net-cash settlement in its own shares (physical settlement or net-share settlement). The Company concluded that the settlement terms of the convertible note hedge, capped call and warrant transactions permit net-share settlement. As such, the convertible note hedge, capped call and warrant transactions were recorded in equity.

At the issuance of the Convertible Notes, the Company bifurcated the $250,000 principal balance of the Convertible Notes into a liability component of $170,885 which was recorded as long-term debt and an equity component of $79,115 which was recorded as additional paid-in-capital. The liability component was recognized at the present value of its associated cash flows using a 7.9% straight-debt rate which represents the Company’s interest rate for similar debt instruments without a conversion feature and is being accreted to interest expense over the term of the Convertible Notes. For the three and nine months ended September 30, 2012, interest expense for the Convertible Notes was $3,549 and $10,514, respectively, which included $1,250 and $3,750 of contractual 2.00% coupon interest, respectively, and $2,299 and $6,764 of non-cash interest accretion expense related to the carrying value of the Convertible Notes, respectively. For both the three and nine months ended September 30, 2011, interest expense for the Convertible Notes was $2,254, which included $833 and $1,421 in coupon interest and interest accretion expense, respectively.

12

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

In accordance with ASC 470-20, which requires issuers to separately account for the liability and equity components of convertible debt instruments that may be settled in cash upon conversion, the Company allocated debt issuance costs to the liability and equity components in proportion to their allocated value. Debt issuance costs were $7,277 with $2,303 recorded as a reduction in additional paid-in-capital. This balance of $4,974 is being amortized over the term of the Convertible Notes. For the three and nine months ended September 30, 2012, total expense associated with the amortization of debt issuance costs was $178 and $533, respectively.

The following table represents the principal balance, the unamortized discount and the net carrying amount of the liability component and the carrying amount of the equity component of the Convertible Notes:

	September 30, 2012			December 31, 2011
Principal balance of liability component	$	250,000		$	250,000
Unamortized discount	(68,735		)	(75,526		)
Carrying amount of liability component	$	181,265		$	174,474
Equity component, net of deferred taxes	$	75,826		$	75,502

The Company had a five-year $200,000 senior credit facility (the “Senior Credit Facility”) until April 25, 2012, which consisted of a $65,000 term loan and a $135,000 revolving credit facility (the “Revolver”) with a scheduled maturity date of May 18, 2015. The Revolver included a $25,000 sub-limit for the issuance of swingline loans and a $50,000 sub-limit to be used for letters of credit. There was a foreign currency limit of $40,000 under the Revolver which could be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permitted borrowings up to $40,000 under the Revolver made by the Company’s wholly-owned subsidiary, Chart Industries Luxembourg S.à r.l. The Senior Credit Facility was amended and restated on April 25, 2012 with a five-year $375,000 senior credit facility (the "Restated Credit Facility"), which consists of a $75,000 term loan (the "Term Loan") and a $300,000 revolving credit facility (the "Revolving Credit Facility"), and the maturity date was extended two years until April 25, 2017. The Revolving Credit Facility includes a $25,000 sub-limit for the issuance of swingline loans and a $100,000 sub-limit to be used for letters of credit. There is a foreign currency limit of $50,000 under the Revolving Credit Facility which could be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permits borrowings up to $50,000 under the Revolver made by the Company’s wholly-owned subsidiary, Chart Industries Luxembourg S.à r.l. The Company recorded $1,445 in deferred financing costs related to the Restated Credit Facility which is being amortized over the five-year term of the loan. In accordance with loan modification accounting guidance, the Company recorded a $232 charge to write off a portion of the remaining deferred financing fees associated with the former Senior Credit Facility. The Restated Credit Facility also includes an expansion option permitting the Company to add up to an aggregate of $150,000 in term loans or revolving credit commitments from its existing and potential new lenders. Loans under the Restated Credit Facility bear interest, at the applicable Borrower's election, at either LIBOR or the greatest of (a) the JPMorgan prime rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% or (c) the Adjusted LIBOR Rate (as defined in the Restated Credit Facility) for a one month interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1%, plus a margin that varies with the Company's net debt to EBITDA ratio. Under the terms of the Restated Credit Facility, 5% of the $75,000 Term Loan is payable annually in quarterly installments over the first three years, 10% is payable annually in quarterly installments over the final two years, and the remaining balance is due on April 25, 2017.

The Restated Credit Facility contains a number of customary covenants, including but not limited to restrictions on the Company’s ability to incur additional indebtedness, create liens or other encumbrances, sell assets, enter into sale and lease-back transactions, make certain payments, investments, loans, advances or guarantees, make acquisitions and engage in mergers or consolidations, pay dividends or distributions, and make capital expenditures. Significant financial covenants for the Restated Credit Facility include a maximum net debt to EBITDA ratio of 3.25 and a minimum interest coverage to EBITDA ratio of 3.0, which are the same limits that applied under the prior Senior Credit Facility. As of September 30, 2012, the Company was in compliance with all covenants. As of September 30, 2012, there was $73,125 outstanding under the Term Loan, $18,387 of borrowings outstanding under the Revolving Credit Facility (average interest rate of 4.25%), and $26,422 in letters of credit issued. As of September 30, 2012, availability under the Revolving Credit Facility was $255,191. The obligations under the Restated Credit Facility are guaranteed by the Company and substantially all of its U.S. subsidiaries and secured by substantially all of the assets of the Company’s U.S. subsidiaries and 65% of the capital stock of the Company’s material non-U.S. subsidiaries (as defined by the Restated Credit Facility) that are owned by U.S. subsidiaries.

13

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

On October 17, 2011, the Company redeemed the $163,175 outstanding principal amount of its 9-1/8% Subordinated Notes which were due in 2015. The redemption price was 103.042% of the principal amount plus accrued and unpaid interest to, but not including, the redemption date, which totaled approximately $175,600. In conjunction with the redemption of the Subordinated Notes, the Company recorded a $4,964 call premium and additional amortization of $2,969 for the write-off of the remaining deferred financing fees related to the Subordinated Notes.

In October 2011, Chart Cryogenic Engineering Systems (Changzhou) Co., Ltd., a wholly-owned subsidiary of the Company, entered into three separate banking facilities (the "Foreign Facilities") which include a bonding/guarantee facility, a revolving line of credit, and an overdraft facility with 30,000, 60,000, and 10,000 Chinese yuan (in thousands) in borrowing capacity, respectively. The Foreign Facilities are guaranteed by the Company. The revolving line of credit has a time to maturity of up to twelve months and was recorded as short-term debt at the date of issuance. As of September 30, 2012, the Company had $4,770 of borrowings outstanding under the revolving line of credit. As of September 30, 2012, there were no amounts outstanding under the overdraft facility or the bonding/guarantee facility.

Chart Ferox, a.s. (Ferox), a wholly-owned subsidiary of the Company, maintains secured credit facilities with capacity of up to 175,000 thousand Czech koruna. Ferox maintains two separate facilities. Both of the facilities allow Ferox to request issuance of bank guarantees and letters of credit. None of the facilities allow revolving credit borrowings, including overdraft protection. Under this first facility, Ferox must pay letter of credit and guarantee fees equal to: (i) 0.70% p.a. on the face amount of each guarantee or letter of credit for maturities of up to 1 year, (ii) 0.80% p.a. for maturities between 1 and 3 years, and (iii) 1.20% p.a. for maturities between 3 and 5 years. Under the second facility, Ferox must pay letter of credit and guarantee fees equal to 0.70% p.a. on the face amount of each guarantee or letter of credit. Ferox is not required to pay a commitment fee to the lender under the second facility. Ferox’s land, buildings and accounts receivable secure the credit facilities. As of September 30, 2012, there were bank guarantees of $897 supported by the Ferox credit facilities.

NOTE D — Restructuring Activities

The Company recorded $359 and $390 for the three and nine months ended September 30, 2012, respectively, in restructuring costs for employee separation benefits primarily related to the integration of SeQual Technologies Inc. These charges were recorded in cost of sales ($318 and $349 for the three and nine months ended September 30, 2012, respectively) and selling, general and administrative expenses ($41 for both the three and nine months ended September 30, 2012).

The Company recorded $696 and $2,905 for the three and nine months ended September 30, 2011, respectively, in restructuring costs related to the closure of the Plainfield, Indiana BioMedical manufacturing facility. The Company also recorded $372 and $1,353 for the three and nine months ended September 30, 2011, respectively, for employee separation benefits related to the integration of SeQual Technologies, Inc. An additional $733 was recorded for the nine months ended September 30, 2011 related to various restructuring efforts across the Company. These charges were recorded in cost of sales ($696 and $1,661 for the three and nine months ended September 30, 2011, respectively) and selling, general and administrative expenses ($372 and $2,114 for the three and nine months ended September 30, 2011, respectively), and a $1,216 loss on disposal of assets for the nine months ended September 30, 2011.

The restructuring liability is recorded in other current liabilities on the condensed consolidated balance sheets. The following tables summarize the Company’s restructuring activities for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2012	$	—	$	6		$	225		$	—	$	231
Restructuring charges	—		—			359			—		359
Cash payments and other	—		(4		)	(329		)	—		(333		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

14

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2012	$	—	$	115		$	998		$	—	$	1,113
Restructuring charges	—		—			390			—		390
Cash payments and other	—		(113		)	(1,133		)	—		(1,246		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2011	$	—	$	157		$	1,966		$	—	$	2,123
Restructuring charges	—		—			1,068			—		1,068
Cash payments and other	—		(43		)	(1,352		)	—		(1,395		)
Balance as of September 30, 2011	$	—	$	114		$	1,682		$	—	$	1,796

	Nine Months Ended September 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of January 1, 2011	$	103		$	388		$	2,088		$	—		$	2,579
Restructuring charges	—			26			4,528			437			4,991
Loss on disposal of assets	—			—			(1,216		)	—			(1,216		)
Cash payments and other	(103		)	(300		)	(3,718		)	(437		)	(4,558		)
Balance as of September 30, 2011	$	—		$	114		$	1,682		$	—		$	1,796

NOTE E — Earnings Per Share

The following table presents calculations of net income per share of common stock for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Net income attributable to Chart Industries, Inc.	$	18,516	$	17,540	$	50,535	$	35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$	0.62	$	0.60	$	1.70	$	1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$	0.61	$	0.59	$	1.68	$	1.19
Weighted average number of common shares outstanding – basic	29,839		29,288		29,743		29,088
Dilutive effect of share-based awards	391		678		412		783
Dilutive effect of convertible debt	13		—		13		—
Weighted average number of common shares outstanding – diluted	30,243		29,966		30,168		29,871

Certain common shares that may be issuable upon the vesting of share-based awards and potential settlements under convertible note hedge and capped call transactions used to offset the dilutive effect of the Convertible Notes were not included in the computation of diluted earnings per share as they were anti-dilutive. There were 116 and 110 anti-dilutive shares for the three and nine months ended September 30, 2012, respectively, and 148 and 97 anti-dilutive shares for the three and nine months ended September 30, 2011, respectively.

15

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

NOTE F — Accumulated Other Comprehensive Income (Loss)

The following tables set forth the changes in accumulated other comprehensive income (loss) by component for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of July 1, 2012	$	10,969	$	(9,155	)	$	1,814
Other comprehensive income, net of tax	2,299		244			2,543
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Nine Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of January 1, 2012	$	12,635	$	(9,642	)	$	2,993
Other comprehensive income, net of tax	633		731			1,364
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Three Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of July 1, 2011	$	22,166		$	(4,945	)	$	17,221
Other comprehensive income (loss), net of tax	(11,137		)	91			(11,046		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

	Nine Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of January 1, 2011	$	14,938		$	(5,127	)	$	9,811
Other comprehensive income (loss), net of tax	(3,909		)	273			(3,636		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

NOTE G — Acquisitions

On August 30, 2012, the Company acquired 100% of the equity interests of AirSep Corporation (AirSep) for an aggregate cash purchase price of $182,450 (including approximately $2,800 in acquisition-related tax benefits acquired and $10,000 of debt which was retired upon completion of the acquisition). The fair value of the net assets acquired and goodwill at the date of acquisition were $83,801 and $98,649, respectively. The allocation of the purchase price was based on the fair value of assets acquired and liabilities assumed, and the related income tax impact of the acquisition adjustments. Goodwill was established due to the benefits that will be derived from the expansion of the Company's BioMedical segment oxygen concentrator business in the U.S. and Europe and growth potential for on-site air separation gas generation.

16

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed in the AirSep acquisition on August 30, 2012. The Company is in the process of obtaining third-party valuations and finalizing other analyses; thus, these provisional measurements are subject to change:

Net assets acquired:
Accounts receivable, net	$	24,280
Inventories, net	32,058
Prepaid expenses	586
Other current assets	3,837
Property, plant and equipment	5,370
Other assets	976
Accounts payable	(11,031		)
Customer advances and billings in excess of contract revenue	(4,782		)
Accrued salaries, wages and benefits	(1,837		)
Other current liabilities	(288		)
Current portion of warranty reserve	(9,920		)
Other long-term liabilities	(11,359		)
Net tangible assets acquired	27,890
Deferred income tax assets	13,051
Goodwill	98,649
Identifiable intangible assets	67,700
Long-term deferred tax liability	(24,840		)
Net assets acquired	$	182,450

AirSep provides warranties on certain of its products, generally for periods of five years or less. The warranty reserve is calculated by considering historical warranty experience and specifically identified warranty issues. AirSep had experienced a significant number of warranty claims in one of its product lines. As of the acquisition date, the Company estimated the expected number of additional product returns based on historical returns experience for this product line. This was then extrapolated to estimate future returns for the remaining warranty periods. Expected future returns were multiplied by the estimated cost to replace the unit to establish a warranty reserve.

AirSep's identifiable intangible assets mainly include customer relationships and technology and is also comprised of trade names, trademarks, and backlog.

For the period August 31, 2012 through September 30, 2012, AirSep added $8,638 to sales. For the same period, the acquisition of AirSep also reduced operating income by $854 which included $608 of intangible asset amortization expense, $855 in amortization expense due to the write up of inventory to fair value, and $278 in management retention expenses. For the three and nine months ended September 30, 2012, the Company recognized $418 and $1,134 of AirSep acquisition related costs, respectively, that were expensed in the current year. These costs are included in the condensed consolidated statements of income and comprehensive income in selling, general and administrative expenses.

On August 1, 2011, Chart Germany GmbH, a wholly-owned subsidiary of the Company, completed the acquisition of 100% of the equity interests of GOFA Gocher Fahrzeugbau GmbH and related companies (GOFA) for a total purchase price of €26,261, net of cash acquired, including a final working capital adjustment of €947. The fair value of the net assets acquired and goodwill at the date of acquisition were $28,372 and $11,438, respectively. The allocation of the purchase price was based on the fair value of assets acquired and liabilities assumed, and the related income tax impact of the acquisition adjustments. Goodwill was established due to the benefits that will be derived from the expansion of the Company's LNG distribution product offering in Europe. GOFA, located in Goch, Germany, designs, manufactures, sells and services cryogenic and noncryogenic mobile equipment. GOFA results are included in the Company’s Distribution & Storage segment and added $13,946 and $2,608 in sales and operating income, respectively, during the nine months ended September 30, 2012.

On April 1, 2011, Chart Inc. completed the acquisition of 100% of the equity of Clever Fellows Innovation Consortium, Inc. (CFIC) for a total potential purchase price of $5,000 in cash, of which $2,000 has been paid. The remaining portion of the

17

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

potential total purchase price represents contingent consideration to be paid over three years based on the attainment of certain revenue targets. The fair value of the net assets acquired and goodwill at the date of acquisition were $732 and $2,938, respectively. The goodwill was established due to the synergistic opportunities to enhance technology for cryogenic applications and grow sales in new product lines. CFIC is located in Troy, New York and develops and manufactures thermoacoustic technology products for cryogenic, heat transfer and related applications. CFIC's results are included in the Company’s BioMedical segment and added $1,198 in sales and reduced operating income by $1,561, during the nine months ended September 30, 2012.

Pro-forma information related to these acquisitions has not been presented because the impact on the Company’s consolidated results of operations is not material.

NOTE H — Income Taxes

The effective tax rate for the three and nine months ended September 30, 2012 of 30.7% and 31.1%, respectively, differs from the U.S. federal statutory rate of 35% primarily due to the effect of income earned by certain of the Company's foreign entities being taxed at lower rates than the federal statutory rate and the positive effect of the domestic production activities deduction. The effective tax rate for the three and nine months ended September 30, 2011 of 28.9% and 30.8%, respectively, differs from the federal statutory rate primarily due to the effect of income earned by certain of the Company’s foreign entities being taxed at lower rates than the U.S. federal statutory rate and the positive effect of the domestic production activities deduction.

As of September 30, 2012, the Company has recorded a $3,457 liability, in accordance with ASC 740-10-25 “Income Taxes,” for gross unrecognized tax benefits. This amount includes $968 of unrecognized tax benefits which, if ultimately recognized, will reduce the Company's annual effective tax rate. During the third quarter of 2012, gross unrecognized tax benefits increased $1,921 due to tax positions taken on prior year returns. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2012, the Company had accrued approximately $114 for the payment of interest and penalties. During the first quarter of 2012, the Internal Revenue Service (IRS) completed an examination of the Company's amended U.S. income tax returns for 2005 and 2006. As a result of the completion of the examination, the Company's gross unrecognized tax benefits decreased by $905.

NOTE I — Employee Benefit Plans

The Company has one defined benefit pension plan which is frozen that covers certain U.S. hourly and salaried employees. The defined benefit plan provides benefits based primarily on the participants’ years of service and compensation.

The following table sets forth the components of net periodic pension expense for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Interest cost	$	552		$	603		$	1,656		$	1,809
Expected return on plan assets	(662		)	(644		)	(1,986		)	(1,932		)
Amortization of net loss	244			91			731			273
Total pension expense	$	134		$	50		$	401		$	150

NOTE J — Reportable Segments

The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company's operating segments: Energy and Chemicals (E&C), Distribution and Storage (D&S) and BioMedical. The Company’s reportable segments are business units that are each managed separately because they manufacture, offer and distribute distinct products with different production processes and sales and marketing approaches. The E&C segment sells brazed aluminum and air-cooled heat exchangers, cold boxes and liquefied natural gas vacuum-insulated pipe to natural gas, petrochemical processing and industrial gas companies who use them for the liquefaction and separation of industrial and natural gases. The D&S segment sells cryogenic bulk storage systems, cryogenic packaged gas systems, cryogenic systems and components, beverage liquid CO₂ systems, cryogenic flow meter systems and cryogenic services to various companies for the storage and transportation of both industrial and natural gases. The BioMedical segment sells medical respiratory products, biological storage systems and other oxygen products. Due to the nature of the products that each segment sells, there are no

18

CHART INDUSTRIES, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements – September 30, 2012

(Dollars and shares in thousands, except per share amounts) – Continued

intersegment sales. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and share-based compensation expenses that are not allocated to the reporting segments.

The Company evaluates performance and allocates resources based on operating income or loss from continuing operations before net interest expense, financing costs amortization expense, foreign currency gain or loss, income taxes and noncontrolling interest. The accounting policies of the reportable segments are the same as those described in Note A.

Information for the Company’s reportable segments and its corporate headquarters is presented below:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	82,968	$	117,752	$	53,529	$	—		$	254,249
Operating income (loss)	17,057		19,948		7,051		(12,024		)	32,032

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	228,921	$	336,278	$	145,095	$	—		$	710,294
Operating income (loss)	44,785		54,447		25,498		(35,754		)	88,976

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	57,777	$	100,911	$	52,623	$	—		$	211,311
Operating income (loss)	12,584		16,109		8,548		(8,198		)	29,043

	Nine Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	149,414	$	275,966	$	149,570	$	—		$	574,950
Operating income (loss)	21,941		44,731		24,218		(26,051		)	64,839

	September 30, 2012		December 31, 2011
Assets:
Energy & Chemicals	$	237,381	$	203,067
Distribution & Storage	580,284		556,688
BioMedical	456,384		226,729
Corporate	49,187		187,991
Total Assets	$	1,323,236	$	1,174,475

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

Chart Industries, Inc. (the “Company,” “Chart,” or “we”) is a leading independent global manufacturer of highly engineered equipment used in the production, storage and end-use of hydrocarbon and industrial gases. The largest portion of end-use applications for our products is energy-related. We are a leading manufacturer of standard and engineered equipment primarily used for low-temperature and cryogenic applications. We have developed an expertise in medical respiratory equipment and cryogenic systems and equipment, which operate at low temperatures sometimes approaching absolute zero (0 kelvin; -273° Centigrade; -459° Fahrenheit). The majority of our products, including vacuum insulated containment vessels, heat exchangers, cold boxes and other cryogenic components, are used throughout the liquid gas supply chain for the purification, liquefaction, distribution, storage and end-use of hydrocarbon and industrial gases.

We continue to see increasing energy demand, particularly for liquefied natural gas (LNG), which drove order and sales growth during the nine months ended September 30, 2012. Orders for the nine months ended September 30, 2012 were $846.5 million. Within our D&S business, we saw strong LNG storage and transportation related orders. However, our Biomedical respiratory business has experienced continued weakness in Europe due to macroeconomic concerns. Backlog as of September 30, 2012 was down slightly to $639.8 million as compared to $648.1 million as of June 30, 2012. Sales for the nine months ended September 30, 2012 were $710.3 million compared to sales of $575.0 million for the nine months ended September 30, 2011, reflecting an increase of $135.3 million, or 23.5% primarily due to higher volume mainly as a result of increased demand for energy equipment as well as higher revenue recognized under percentage of completion as we continue work on several large LNG related projects in our E&C business. Sales also benefited from the acquisitions of AirSep Corporation (AirSep) in August 2012, and GOFA Gocher Fahrzeugbau GmbH (GOFA) in August 2011. Gross profit for the nine months ended September 30, 2012 was $219.7 million, or 30.9% of sales, as compared to $181.4 million, or 31.6% of sales, for the nine months ended September 30, 2011. Higher volume in our E&C and D&S segments and favorable product mix, offset by costs associated with facility expansion projects and additional resources to support growth in the U.S. and Asia contributed to the increase in gross profit and the slight decline in the gross margin percentage. Operating income for the nine months ended September 30, 2012 was $89.0 million compared to $64.8 million for the nine months ended September 30, 2011.

20

The following table sets forth sales, gross profit, gross profit margin and operating income or loss for our operating segments for the three and nine months ended September 30, 2012 and 2011 (dollars in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Sales
Energy & Chemicals	$	82,968		$	57,777		$	228,921		$	149,414
Distribution & Storage	117,752			100,911			336,278			275,966
BioMedical	53,529			52,623			145,095			149,570
Total	$	254,249		$	211,311		$	710,294		$	574,950
Gross Profit
Energy & Chemicals	$	24,255		$	19,121		$	69,264		$	45,180
Distribution & Storage	35,678			28,455			95,968			78,898
BioMedical	18,079			19,055			54,466			57,369
Total	$	78,012		$	66,631		$	219,698		$	181,447
Gross Profit Margin
Energy & Chemicals	29.2		%	33.1		%	30.3		%	30.2		%
Distribution & Storage	30.3		%	28.2		%	28.5		%	28.6		%
BioMedical	33.8		%	36.2		%	37.5		%	38.4		%
Total	30.7		%	31.5		%	30.9		%	31.6		%
Operating Income (Loss)
Energy & Chemicals	$	17,057		$	12,584		$	44,785		$	21,941
Distribution & Storage	19,948			16,109			54,447			44,731
BioMedical	7,051			8,548			25,498			24,218
Corporate	(12,024		)	(8,198		)	(35,754		)	(26,051		)
Total	$	32,032		$	29,043		$	88,976		$	64,839

Results of Operations for the Three Months Ended September 30, 2012 and 2011

Sales

Sales for the three months ended September 30, 2012 were $254.2 million compared to $211.3 million for the three months ended September 30, 2011, reflecting an increase of $42.9 million, or 20.3%. The primary drivers of the increase in sales were improved volume and the impact of acquisitions. E&C segment sales were $83.0 million for the three months ended September 30, 2012, compared with sales of $57.8 million for the three months ended September 30, 2011, which was an increase of $25.2 million or 43.6%. This increase in E&C sales for the three months ended September 30, 2012 was primarily due to the ramp up of several large LNG related projects in our brazed aluminum heat exchanger and systems business. D&S segment sales increased$16.9 million, or 16.7%, to $117.8 million for the three months ended September 30, 2012, from $100.9 million for the three months ended September 30, 2011. The increase in sales was largely due to improved volume, particularly in LNG applications, including mobile equipment, and bulk storage tanks. Sales for bulk storage systems and package gas systems increased $8.1 million and $8.7 million, respectively. Acquisitions added $2.2 million in sales during the three months ended September 30, 2012. BioMedical segment sales for the three months ended September 30, 2012 were $53.5 million compared to $52.6 million for the same period in 2011, which reflected an increase of $0.9 million, or 1.7%. AirSep, which was acquired in August 2012, contributed $8.6 million in sales during the quarter. The incremental sales associated with the AirSep acquisition were largely offset by lower volume in respiratory sales due to the overall macroeconomic weaknesses in Europe and continued phase-in of Medicare competitive bidding in the U.S.

Gross Profit and Margin

Gross profit for the three months ended September 30, 2012 was $78.0 million, or 30.7% of sales, versus $66.6 million, or 31.5% of sales, for the three months ended September 30, 2011 and reflected an increase of $11.4 million. E&C segment gross profit increased$5.1 million while its margin decreased3.9 percentage points. During the third quarter of 2011, approximately 3.0 percentage points of E&C margin was added due to the sale of equipment which had been written off in

21

prior years thereby inflating E&C margin in the prior year's quarter. The remaining 0.9 percentage point reduction in E&C gross margin was due to changes in project mix between periods. Gross profit for the D&S segment increased$7.2 million and margin increased 2.1 percentage points due to higher volume and improved capacity utilization. BioMedical gross profit decreased$1.0 million as margin decreased2.4 percentage points for the three months ended September 30, 2012 as compared to the same period in 2011. BioMedical margins were lower in the three months ended September 30, 2012 compared to the prior year quarter due to lower volume and unfavorable product mix in respiratory products due to increased concentrator sales.

Selling, General and Administrative Expenses (SG&A)

SG&A expenses for the three months ended September 30, 2012 were $42.2 million, or 16.6% of sales, compared to $34.1 million, or 16.1% of sales, for the three months ended September 30, 2011. SG&A expenses for the E&C segment were $6.4 million for the three months ended September 30, 2012 compared to $6.2 million for the three months ended September 30, 2011, an increase of $0.2 million. D&S segment SG&A expenses for the three months ended September 30, 2012 were $14.5 million compared to $11.2 million for the three months ended September 30, 2011, an increase of $3.3 million. This increase was primarily attributable to the acquisition of GOFA in August 2011, increased employee-related costs, and higher marketing and sales commission expense due to increased sales volume. SG&A expenses for the BioMedical segment were $9.3 million for the three months ended September 30, 2012 and $8.5 million for the three months ended September 30, 2011. The increase of $0.8 million was primarily attributable to the AirSep acquisition which contributed $1.6 million in SG&A expenses during the quarter offset by a decrease of $0.8 million due to lower employee-related costs and professional services. Corporate SG&A expenses for the three months ended September 30, 2012 were $12.0 million, compared to $8.2 million for the three months ended September 30, 2011. This increase of $3.8 million was primarily attributable to higher employee-related costs, information system upgrades, and fees for professional services to support organic and inorganic growth.

Amortization Expense

Amortization expense for the three months ended September 30, 2012 was $3.8 million, or 1.5% of sales, and $3.3 million, or 1.6% of sales, for the three months ended September 30, 2011. The AirSep acquisition added $0.6 million of amortization expense during the quarter.

Operating Income

As a result of the foregoing, operating income for the three months ended September 30, 2012 was $32.0 million, or 12.6% of sales, an increase of $3.0 million compared to operating income of $29.0 million, or 13.7% of sales, for the same period in 2011.

Net Interest Expense and Financing Costs Amortization

Net interest expense for the three months ended September 30, 2012 and 2011 was $4.0 million and $6.4 million, respectively. Interest expense for the three months ended September 30, 2012 included $1.3 million of contractual 2.00% coupon interest and $2.3 million of non-cash interest accretion expense related to the carrying value of the Convertible Senior Subordinated Notes (the “Convertible Notes”). Interest expense was higher by $2.4 million for the three months ended September 30, 2011 as the Convertible Notes and the Company's previously outstanding 9-1/8% Senior Subordinated Notes were both outstanding for approximately two months during the period. Financing costs amortization was $0.3 million and $0.4 million for the three months ended September 30, 2012 and 2011, respectively.

Foreign Currency Losses (Gains)

For the three months ended September 30, 2012 and 2011, foreign currency losses were $0.5 million and foreign currency gains were $2.4 million, respectively. Losses increased by $2.9 million as a result of increased volatility in foreign exchange rates, particularly the euro, impacting transactions denominated in foreign currencies for the three months ended September 30, 2012.

Income Tax Expense

Income tax expense of $8.4 million and $7.1 million for the three months ended September 30, 2012 and 2011, respectively, represents taxes on both U.S. and foreign earnings at a combined effective income tax rate of 30.7% and 28.9%, respectively. The increase in the effective tax rate for the three months ended September 30, 2012 compared to the prior year period is primarily due to a decrease in the mix of income earned by certain of the Company's foreign entities which are taxed at lower rates than the U.S. federal statutory rate.

22

Net Income

As a result of the foregoing, reported net income attributable to the Company for the three months ended September 30, 2012 and 2011 was $18.5 million and $17.5 million, respectively.

Results of Operations for the Nine Months Ended September 30, 2012 and 2011

Sales

Sales for the nine months ended September 30, 2012 were $710.3 million compared to $575.0 million for the nine months ended September 30, 2011, reflecting an increase of $135.3 million, or 23.5%. The primary drivers of the increase in sales were improved volume, particularly in the E&C and D&S business segments, and the impact of acquisitions. E&C segment sales were $228.9 million for the nine months ended September 30, 2012, compared with sales of $149.4 million for the nine months ended September 30, 2011, which was an increase of $79.5 million or 53.2%. This increase in E&C sales for the nine months ended September 30, 2012 was primarily due to improved volume in all product lines, particularly LNG and natural gas related opportunities including revenue recognized under percentage of completion as we ramp up production on several large LNG projects in backlog. D&S segment sales increased$60.3 million, or 21.9%, to $336.3 million for the nine months ended September 30, 2012, from $276.0 million for the nine months ended September 30, 2011. The increase in sales was largely due to improved volume, particularly in LNG applications, including mobile equipment, and bulk storage tanks. Sales for bulk storage systems and package gas systems increased $44.4 million and $15.9 million, respectively. Acquisitions added $11.4 million in sales during the nine months ended September 30, 2012. BioMedical segment sales for the nine months ended September 30, 2012 were $145.1 million compared to $149.6 million for the same period in 2011, which reflected a decrease of $4.5 million, or 3.0%. The decrease was mainly due to lower volume in respiratory sales due to the weaker euro given the overall macroeconomic concerns in Europe and continued phase-in of Medicare competitive bidding in the U.S. This reduction was partially offset by $8.6 million in sales contributed by AirSep during the period, which was acquired in August 2012.

Gross Profit and Margin

Gross profit for the nine months ended September 30, 2012 was $219.7 million, or 30.9% of sales, versus $181.4 million, or 31.6% of sales, for the nine months ended September 30, 2011 and reflected an increase of $38.3 million. E&C segment gross profit increased$24.1 million and its margin increased0.1 percentage points primarily due to higher production throughput and improved pricing, partially offset by higher training costs as production continues to ramp up on several large LNG projects in backlog. Gross profit for the D&S segment increased$17.1 million due to higher volume and improved capacity utilization. Margin declined0.1 percentage points primarily due to unfavorable product mix and facility ramp up costs associated with several capacity expansion projects in the U.S. and Asia. BioMedical gross profit decreased$2.9 million and margin decreased0.9 percentage points for the nine months ended September 30, 2012 as compared to the same period in 2011. The decrease in gross profit and margin percentage is primarily due to lower volume and unfavorable product mix from respiratory products due to increased concentrator sales partially offset by $1.4 million in gross margin contributed by AirSep during the period.

Selling, General and Administrative Expenses (SG&A)

SG&A expenses for the nine months ended September 30, 2012 were $117.5 million, or 16.5% of sales, compared to $105.3 million, or 18.3% of sales, for the nine months ended September 30, 2011. SG&A expenses for the E&C segment were $21.9 million for the nine months ended September 30, 2012 compared to $21.1 million for the nine months ended September 30, 2011, an increase of $0.8 million. The increase was primarily attributable to higher employee-related costs and fees for professional services to support growth partially offset by lower sales commissions. D&S segment SG&A expenses for the nine months ended September 30, 2012 were $37.8 million compared to $30.5 million for the nine months ended September 30, 2011, an increase of $7.3 million. This increase was primarily attributable to the acquisition of GOFA in August 2011, increased employee-related costs due to LNG growth, higher marketing and sales commission expense, and fees for professional services. SG&A expenses for the BioMedical segment were $22.0 million for the nine months ended September 30, 2012 and $27.7 million for the nine months ended September 30, 2011. The decrease of $5.7 million was mainly the result of a $4.6 million acquisition-related contingent consideration fair value adjustment that reduced SG&A expenses in the second quarter of 2012 and lower fees for professional services during the nine months ended September 30, 2012. This was partially offset by AirSep, acquired in August 2012, which contributed $1.6 million in SG&A expenses during the period. Corporate SG&A expenses for the nine months ended September 30, 2012 were $35.8 million, compared to $26.0 million for the nine months ended September 30, 2011. This increase of $9.8 million was primarily attributable to higher employee-related costs, share-based compensation expense, information systems upgrades, and fees for professional services to support organic and inorganic growth.

23

Amortization Expense

Amortization expense for the nine months ended September 30, 2012 was $10.1 million, or 1.4% of sales, compared to $9.9 million, or 1.7% of sales for the nine months ended September 30, 2011. The AirSep acquisition added $0.6 million of amortization expense during the period.

Impairment of Intangible Assets/Loss on Disposal of Assets

During the nine months ended September 30, 2012, the Company recorded an impairment charge of $3.1 million to reduce the carrying value of in-process research and development (IPR&D) intangible assets to fair value which was zero as of the end of the second quarter 2012. The adjustments to the fair value of the IPR&D intangible assets was primarily caused by higher forecasted costs and project delays.

A loss on disposal of assets of $1.3 million was recorded for the nine months ended September 30, 2011 mainly as a result of the disposal of the remaining assets at the BioMedical Plainfield, Indiana facility as part of the final closure of the facility in May 2011. Production was transferred to the new Canton, Georgia BioMedical facility during the nine months ended September 30, 2011.

Operating Income

As a result of the foregoing, operating income for the nine months ended September 30, 2012 was $89.0 million, or 12.5% of sales, an increase of $24.2 million compared to operating income of $64.8 million, or 11.3% of sales, for the same period in 2011.

Net Interest Expense and Financing Costs Amortization

Net interest expense for the nine months ended September 30, 2012 and 2011 was $11.7 million and $14.4 million, respectively. Interest expense for the nine months ended September 30, 2012 included $3.8 million of contractual 2.00% coupon interest and $6.8 million of non-cash interest accretion expense related to the carrying value of the Convertible Notes. Interest expense was higher by $2.4 million for the nine months ended September 30, 2011 as the Convertible Notes and the Company's previously outstanding 9-1/8% Senior Subordinated Notes were both outstanding for approximately two months during the period. Financing costs amortization was $1.2 million and $1.1 million for the nine months ended September 30, 2012 and 2011, respectively.

Foreign Currency Losses (Gains)

For the nine months ended September 30, 2012, foreign currency losses were $1.9 million while foreign currency gains were $2.5 million for the nine months ended September 30, 2011. The $4.4 million change is primarily attributable to increased volatility in foreign exchange rates, particularly the euro, impacting transactions denominated in foreign currencies and unrealized losses on the Company's foreign currency forward contracts during the nine months ended September 30, 2012.

Income Tax Expense

Income tax expense of $23.1 million and $16.0 million for the nine months ended September 30, 2012 and 2011, respectively, represents taxes on both U.S. and foreign earnings at a combined effective income tax rate of 31.1% and 30.8%, respectively. The increase in the effective tax rate, for the nine months ended September 30, 2012 compared to the prior year period is primarily due to a decrease in the mix of income earned by certain of the Company's foreign entities which are taxed at lower rates than the U.S. federal statutory rate.

Net Income

As a result of the foregoing, reported net income attributable to the Company for the nine months ended September 30, 2012 and 2011 was $50.5 million and $35.7 million, respectively.

Liquidity and Capital Resources

Debt Instruments and Related Covenants

The Company had a $200.0 million senior credit facility (the “Senior Credit Facility”) until April 25, 2012, which consisted of a $65.0 million term loan and a $135.0 million revolving credit facility with a scheduled maturity date of May 18, 2015. Under the terms of the facility, 10% of the $65.0 million term loan was payable in quarterly installments of $1.6 million with the balance due in 2015. The Senior Credit Facility was amended on April 25, 2012 with a five-year $375.0 million senior credit facility (the "Restated Credit Facility"), which consists of a $75.0 million term loan (the "Term Loan") and a $300.0

24

million revolving credit facility (the "Revolving Credit Facility"), and the maturity date was extended two years until April 25, 2017. The Company recorded $1.4 million in deferred financing costs related to the Restated Credit Facility which is being amortized over the five-year term of the loan. The Restated Credit Facility also includes an expansion option permitting the Company to add up to an aggregate $150.0 million in term loans or revolving credit commitments from its existing and potential new lenders. Loans under the Restated Credit Facility bear interest, at the applicable Borrower's election, at either LIBOR or the greatest of (a) the JPMorgan prime rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% or (c) the Adjusted LIBOR Rate (as defined in the Restated Credit Facility) for a one month interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1%, plus a margin that varies with the Company's net debt to EBITDA ratio. Under the terms of the Restated Credit Facility, 5% of the $75.0 million Term Loan is payable annually in quarterly installments over the first three years, 10% is payable annually in quarterly installments over the final two years, and the remaining balance is due on April 25, 2017. Significant financial covenants for the Restated Credit Facility include a maximum net debt to EBITDA ratio of 3.25 and a minimum interest coverage to EBITDA ratio of 3.0, which are the same limits that applied under the prior Senior Credit Facility. As of September 30, 2012, there was $73.1 million outstanding under the Term Loan and borrowings of $18.4 million under the Revolving Credit Facility. The Company also had $26.4 million of letters of credit and bank guarantees supported by the Revolving Credit Facility and availability was $255.2 million. The Company was in compliance with all covenants, including its financial covenants, as of September 30, 2012.

On August 3, 2011, the Company closed on its offering of $250.0 million aggregate principal amount of 2.00% Convertible Notes (the "Convertible Notes"). Upon conversion, holders of the Convertible Notes will receive cash up to the principal amount of the Convertible Notes, and it is Chart’s intention to settle any excess conversion value in shares of Chart’s common stock. However, Chart may elect to settle, at its discretion, any such excess value in cash, shares of Chart’s common stock or a combination of cash and shares. The initial conversion price of approximately $69.03 per share represents a conversion premium of 30% over the last reported sale price of Chart’s common stock on July 28, 2011, which was $53.10 per share. The net proceeds from the offering were approximately $242.7 million after deducting the underwriters’ discount and offering expenses. Approximately $17.6 million of the net proceeds from the Convertible Notes were used to pay the cost of the convertible note hedge and capped call transactions described in Note C of the unaudited condensed consolidated financial statements included in this report, taking into account the proceeds to the Company from the sale of related warrant transactions.

On October 17, 2011, the Company redeemed the entire outstanding principal amount of its $163.2 million Subordinated Notes at a redemption price of 103.042% of the principal plus accrued and unpaid interest. During the fourth quarter of 2011, the Company wrote off the carrying value of deferred financing fees related to the Subordinated Notes, which totaled approximately $3.0 million.

In October 2011, Chart Cryogenic Engineering Systems (Changzhou) Co., Ltd., a wholly-owned subsidiary of the Company, entered into three separate banking facilities (the "Foreign Facilities") which include a bonding/guarantee facility, a revolving line of credit, and an overdraft facility with 30.0 million, 60.0 million, and 10.0 million Chinese yuan in borrowing capacity, respectively. The Foreign Facilities are guaranteed by the Company. The revolving line of credit has a time to maturity of up to twelve months and was recorded as short-term debt at the date of issuance. As of September 30, 2012, the Company had $4.8 million of borrowings outstanding under the revolving line of credit. As of September 30, 2012, there were no amounts outstanding under the overdraft facility or the bonding/guarantee facility.

Chart Ferox, a.s., or Ferox, our wholly-owned subsidiary that operates in the Czech Republic, maintains secured revolving credit facilities with capacity of up to 175.0 million Czech korunas. Both of the facilities allow Ferox to request issuance of bank guarantees and letters of credit. As of September 30, 2012, there were $0.9 million of bank guarantees supported by such facilities.

Sources and Use of Cash

Our cash and cash equivalents totaled $105.8 million as of September 30, 2012, a decrease of $151.1 million from the balance as of December 31, 2011 mainly due to the acquisition of AirSep. As of September 30, 2012, cash of approximately $103.2 million was maintained in accounts in various foreign subsidiaries and used to meet the liquidity needs of our foreign subsidiaries. As of September 30, 2012, Chart Cryogenic Distribution Equipment (Changzhou) Company Limited, a joint venture of the Company, and Chart Cryogenic Engineering Systems (Changzhou) Company Limited held $1.1 million and $0.8 million in restricted cash on deposit, respectively, to cover guarantees. No material restrictions exist in accessing cash held by our foreign subsidiaries and we expect to meet our U.S. funding needs without repatriating non-U.S. cash and incurring the resulting incremental U.S. taxes. Cash equivalents are invested in money market funds that invest in high quality, short-term instruments, such as U.S. government obligations, certificates of deposit, repurchase obligations and commercial paper issued by corporations that have been highly rated by at least one nationally recognized rating organization. We believe that our

25

existing cash and cash equivalents, funds available under our debt facilities and cash provided by operations will be sufficient to finance our normal working capital needs, acquisition obligations, and investments in properties, facilities and equipment for the foreseeable future.

Cash provided by operating activities for the nine months ended September 30, 2012 was $14.5 million compared with cash provided by operating activities of $37.0 million for the nine months ended September 30, 2011. The decrease of $22.5 million in cash provided by operations was primarily the result of a decrease in billings in excess of contract revenue due to progress made on several large E&C system orders in backlog during 2012.

Cash used in investing activities for the nine months ended September 30, 2012 was $209.7 million compared to cash used in investing activities of $52.5 million for the nine months ended September 30, 2011. In August 2012, the Company used $182.5 million in cash to fund the AirSep acquisition as compared to $37.7 million used for acquisitions during the nine months ended September 30, 2011. Capital expenditures for the nine months ended September 30, 2012 were $29.0 million compared with $15.2 million for the nine months ended September 30, 2011. Major capital expenditures for the nine months ended September 30, 2012 included capacity expansion projects in D&S and E&C in response to strong order intake and expected future growth. Also during the nine months ended September 30, 2012, the Company received $2.0 million in proceeds for the sale of assets previously held for sale.

Cash provided by financing activities for the nine months ended September 30, 2012 and 2011 was $40.2 million and $229.8 million, respectively. During the nine months ended September 30, 2012, the Company received $21.4 million in proceeds from its Term Loan and $18.4 million from its Revolving Credit Facility which was offset by $1.4 million in payments for financing fees and a $1.3 million contingent consideration payment for the Cryotech acquisition. Also during the nine months ended September 30, 2012, the Company made $3.5 million in scheduled quarterly principal payments on the term loan portions of both the former Senior Credit Facility and Restated Credit Facility. The Company also had a $7.9 million tax benefit from the exercise of stock options and received $3.3 million in proceeds for stock option exercises which were offset by $4.5 million for common stock repurchases to cover tax withholding elections during the nine months ended September 30, 2012.

Cash Requirements

The Company does not anticipate any unusual cash requirements for working capital needs for the year ending December 31, 2012. Management anticipates the Company will be able to satisfy cash requirements for its ongoing business for the foreseeable future with cash generated by operations, existing cash balances and, if necessary, borrowings under our credit facilities. We also expect capital expenditures for the remainder of 2012 to be in the range of $15.0 to $20.0 million, primarily for continued automation, process improvements and/or expansions at existing manufacturing facilities, support of anticipated business growth in specific product lines and acquisition integration.

For the remainder of 2012, the Company is forecasting to use approximately $0.4 million for scheduled interest payments under the Restated Credit Facility. We are also required to make quarterly principal payments of $0.9 million for the remainder of the 2012 under the Restated Credit Facility. In addition, our forecasts for the remainder of 2012 contemplate the use of approximately $12.0 to $13.0 million of cash to pay U.S. and foreign income taxes.

Orders and Backlog

We consider orders to be those for which we have received a firm signed purchase order or other written contractual commitment from the customer. Backlog is comprised of the portion of firm signed purchase orders or other written contractual commitments received from customers that we have not recognized as revenue upon shipment or under the percentage of completion method. Backlog can be significantly affected by the timing of orders for large projects, particularly in the E&C segment, and is not necessarily indicative of future backlog levels or the rate at which backlog will be recognized as sales. Orders included in our backlog may include customary cancellation provisions under which the customer could cancel part or all of the order, potentially subject to the payment of certain costs and/or penalties. Our backlog as of September 30, 2012 was $639.8 million compared to $648.1 million as of June 30, 2012.

26

The following table sets forth orders and backlog by segment for the periods indicated (dollars in thousands):

	Three Months Ended
	September 30, 2012		June 30, 2012
Orders
Energy & Chemicals	$	56,435	$	58,119
Distribution & Storage	120,388		121,376
BioMedical	56,598		48,459
Total	$	233,421	$	227,954
Backlog
Energy & Chemicals	$	397,741	$	424,005
Distribution & Storage	214,377		211,963
BioMedical	27,708		12,173
Total	$	639,826	$	648,141

E&C orders for the three months ended September 30, 2012 were $56.4 million compared to $58.1 million for the three months ended June 30, 2012. E&C backlog totaled $397.7 million at September 30, 2012, compared to $424.0 million as of June 30, 2012 which included orders in excess of $150.0 million for two large LNG baseload projects in Australia during the first quarter of 2012. Order flow in the E&C segment is historically volatile due to project size and it is not unusual to see order intake change significantly quarter to quarter.

D&S orders for the three months ended September 30, 2012 were $120.4 million compared to $121.4 million for the three months ended June 30, 2012. D&S order trends were strong in China which partially offset shortfalls in Europe. D&S backlog totaled $214.4 million at September 30, 2012 compared to $212.0 million as of June 30, 2012.

BioMedical orders for the three months ended September 30, 2012 were $56.6 million compared to $48.5 million for the three months ended June 30, 2012 and included $11.6 million in orders associated with our August 2012 acquisition of AirSep. Excluding AirSep, orders were down due to continued weakness in Europe. BioMedical backlog at September 30, 2012 totaled $27.7 million compared to $12.2 million as of June 30, 2012.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Application of Critical Accounting Policies

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. As such, some accounting policies have a significant impact on amounts reported in these unaudited condensed consolidated financial statements. A summary of those significant accounting policies can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. In particular, judgment is used in areas such as revenue recognition for long-term contracts, determining the allowance for doubtful accounts, inventory valuation reserves, goodwill, indefinite lived intangibles, contingent liabilities, environmental remediation obligations, product warranty costs, debt covenants, pensions and deferred tax assets. There have been no significant changes in accounting policies since December 31, 2011.

Forward-Looking Statements

The Company is making this statement in order to satisfy the “safe harbor” provisions contained in the Private Securities Litigation Reform Act of 1995. This Quarterly Report on Form 10-Q includes “forward-looking statements”. These forward-looking statements include statements relating to our business. In some cases, forward-looking statements may be identified by terminology such as “may,” “should,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “continue” or the negative of such terms or comparable terminology. Forward-looking statements contained herein (including future cash contractual obligations, liquidity, cash flow, orders, results of operations, projected revenues from new acquisitions, and trends, among other matters) or in other statements made by us are made based on management’s expectations and beliefs concerning future events impacting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by forward-looking statements. We believe that the following factors, among others (including those described under Item 1A– “Risk Factors”, of our Annual Report on Form 10-K for the year ended December 31, 2011), could affect our future performance and the liquidity and value of our securities and cause our actual results to differ materially from those expressed or implied by forward-looking statements made by us or on our behalf:

27

• the cyclicality of the markets which we serve and the vulnerability of those markets to economic downturns;

• the loss of, or a significant reduction or delay in purchases by our largest customers;

• the fluctuations in energy prices;

• governmental energy policies could change, or expected changes could fail to materialize;

• the potential for negative developments in the natural gas industry related to hydraulic fracturing;

• competition in our markets;

• economic downturns and deteriorating financial conditions;

• our ability to manage our fixed-price contract exposure;

• our reliance on the availability of key supplies and services;

• degradation of our backlog as a result of modification or termination of orders;

• our ability to successfully manage our planned operational expansions;

• changes in government health care regulations and reimbursement policies;

• general economic, political, business and market risks associated with our global operations including the instability in North Africa and the Middle East and any expansion thereof;

• our ability to successfully acquire or integrate companies that provide complementary products or technologies, including the successful integration of the AirSep acquisition;

• fluctuations in foreign currency exchange rates and interest rates;

• financial distress of third parties;

• the loss of key employees;

• the pricing and availability of raw materials;

• our ability to control our costs while maintaining customer relationships and core business resources;

• litigation and disputes involving us, including the extent of product liability, warranty, contract, employment and environmental claims asserted against us;

• United States Food and Drug Administration and comparable foreign regulation of our products;

• the impairment of our goodwill or other intangible assets;

• the cost of compliance with environmental, health and safety laws and responding to potential liabilities under these laws;

• labor costs and disputes and the deterioration of our relations with our employees;

• additional liabilities related to taxes;

• the underfunded status of our pension plan;

• our ability to continue our technical innovation in our product lines;

• our ability to protect our intellectual property and know-how;

• claims that our products or processes infringe intellectual property rights of others;

• disruptions in our operations due to severe weather;

• potential violations of the Foreign Corrupt Practices Act;

• increased government regulation;

• regulations governing the export of our products and other regulations applicable to us as a supplier of products to the U.S. government;

• technological security threats and our reliance on information systems;

• risks associated with our indebtedness, leverage, debt service and liquidity;

• potential dilution to existing holders of our common stock as a result of the conversion of our convertible debt;

• fluctuations in the price of our stock; and

• other factors described herein.

There may be other factors that may cause our actual results to differ materially from the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date of this Quarterly Report and are expressly qualified in their entirety by the cautionary statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as the same may be updated from time to time. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the filing date of this document or to reflect the occurrence of unanticipated events.

28

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In the normal course of business, the Company’s operations are exposed to fluctuations in foreign currency values and interest rates that can affect the cost of operating and financing. Accordingly, the Company addresses a portion of these risks through a program of risk management.

Interest Rate Risk: The Company’s primary interest rate risk exposure results from the Restated Credit Facility's various floating rate pricing mechanisms. If interest rates were to increase 200 basis points (2 percent) from September 30, 2012 rates, and assuming no changes in debt from the September 30, 2012 levels, the additional annual expense would be approximately $1.8 million on a pre-tax basis.

Foreign Currency Exchange Rate Risk: The Company has assets, liabilities and cash flows in foreign currencies creating exposure to foreign currency exchange fluctuations in the normal course of business. Chart’s primary exchange rate exposures are with the euro, the British pound, the Czech koruna, the Japanese yen and the Chinese yuan. Monthly measurement, evaluation and forward exchange rate contracts are employed as methods to reduce this risk. The Company enters into foreign exchange forward contracts to hedge anticipated and firmly committed foreign currency transactions. Chart does not use derivative financial instruments for speculative or trading purposes. The terms of the contracts are generally one year or less. At September 30, 2012, the Company had foreign exchange contracts with notional amounts of (i) 48,700,000 euros to sell against the U.S. dollar, (ii) 2,280,000 euros to sell against the Czech koruna, (iii) 800,000 Australian dollars against the U.S. dollar, (iv) 60,000,000 Japanese yen to sell against the U.S. dollar, (v) 700,000 British pounds to sell against the U.S. dollar, (vi) 510,000 British pounds to sell against the Czech koruna, (vii) 980,000 U.S. dollars against the Czech koruna, and (viii) 200,000 British pounds to sell against the euro. At September 30, 2012, a hypothetical 10% weakening of the U.S. dollar would not materially affect the Company’s financial statements.

Market Price Sensitive Instruments

In connection with the issuance of the Convertible Notes, the Company entered into privately-negotiated convertible note hedge and capped call transactions with affiliates of certain of the underwriters (the “Option Counterparties”). The convertible note hedge and capped call transactions relate to, collectively, 3.6 million shares, which represents the number of shares of the Company’s common stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes. These convertible note hedge and capped call transactions are expected to reduce the potential dilution with respect to the Company’s common stock upon conversion of the Convertible Notes and/or reduce the Company’s exposure to potential cash or stock payments that may be required upon conversion of the Convertible Notes, except, in the case of the capped call transactions, to the extent that the market price per share of the Company’s common stock exceeds the cap price of the capped call transactions.

The Company also entered into separate warrant transactions with the Option Counterparties initially relating to the number of shares of the Company’s common stock underlying the convertible note hedge transactions, subject to customary anti-dilution adjustments. The warrant transactions will have a dilutive effect with respect to the Company’s common stock to the extent that the price per share of the Company's common stock exceeds the strike price of the warrants unless the Company elects, subject to certain conditions, to settle the warrants in cash. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. Further information is located in Note C to the Company’s condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 4. Controls and Procedures

As of September 30, 2012, an evaluation was performed, under the supervision and with the participation of the Company’s management including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, such officers concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act (1) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (2) is accumulated and communicated to the Company’s management including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

There were no changes in the Company’s internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

29

PART II. OTHER INFORMATION

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

a.) None.

b.) None.

c.) During the third quarter of 2012, we repurchased 650 shares of common stock to satisfy tax withholding obligations relating to the vesting or payment of equity awards for an aggregate purchase price of approximately $46,000. The total number of shares repurchased represents the net shares issued to satisfy tax withholding. All such repurchased shares were subsequently retired during the three months ended September 30, 2012.

	Issuer Purchases of Equity Securities
Period	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 – 31, 2012	124	$	67.95	—	$	—
August 1 – 31, 2012	526	71.00		—	—
September 1 – 30, 2012	—	—		—	—
Total	650	$	70.42	—	$	—

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

On October 31, 2012, Chart Energy & Chemicals, Inc. (“Chart E&C”), which is a wholly owned indirect subsidiary of the Company, and Local Lodge 2191 of District Lodge 66 of The International Association of Machinists and Aerospace Workers (the “Union”) entered into a new five-year collective bargaining agreement (the “Collective Bargaining Agreement”), which will replace the current bargaining agreement between Chart E&C and the Union upon its expiration on February 2, 2013. The Collective Bargaining Agreement covers approximately 440 production and maintenance workers at the Chart E&C facility in La Crosse, Wisconsin. The five-year term will extend from February 3, 2013 to February 3, 2018.  The Collective Bargaining Agreement includes terms customary in collective bargaining agreements and is substantially similar to the previous collective bargaining agreement between Chart E&C and the Union, which was previously filed with the Securities and Exchange Commission as Exhibit 10.5 to the Company's quarterly report on Form 10-Q filed on April 29, 2010, with changes from the previous agreement primarily related to wages, retirement benefits and other terms customary in collective bargaining agreements.

Item 6. Exhibits

The following exhibits are included with this report:

2.1 Agreement and Plan of Merger, dated as of July 23, 2012 by and among Chart Inc., Bison Corp., AirSep Corporation, Joseph L. Priest, as Representative, for purposes of Section 4.10 only, Joseph L. Priest and Ravinder K. Bansal, and for purposes of Section 9.14 only, Chart Industries, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on 8-K filed with the SEC on July 23, 2012 (File No. 001-11442)).*

2.2 Amendment No. 1 to Agreement and Plan of Merger, dated as of August 30, 2012 by and among Chart Inc., Bison Corp., AirSep Corporation, Joseph L. Priest, as Representative, for purposes of Section 4.10 only, Joseph L. Priest and Ravinder K. Bansal, and for purposes of Section 9.14 only, Chart Industries, Inc. (x)

30

10.1 Amendment No. 1 to the Chart Industries, Inc. Amended and Restated 2009 Omnibus Equity Plan. (x)

31.1 Rule 13a-14(a) Certification of Chief Executive Officer (x)

31.2 Rule 13a-14(a) Certification of Chief Financial Officer (x)

32.1 Section 1350 Certification of Chief Executive Officer (xx)

32.2 Section 1350 Certification of Chief Financial Officer (xx)

101 The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flow, (iv) the Notes to Condensed Consolidated Financial Statements. **

(x) Filed herewith

(xx) Furnished herewith

* The exhibits and schedules of the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K, and will be provided to the Securities and Exchange Commission upon request.

** In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act of 1933 or Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chart Industries, Inc.

(Registrant)

Date:	November 1, 2012	By:	/s/ Michael F. Biehl
			Michael F. Biehl
			Executive Vice President, Chief Financial Officer and Treasurer
			(Principal Financial Officer)
			(Duly Authorized Officer)

32

EX-2.2

Exhibit 2.2

AMENDMENT NO. 1

TO

AGREEMENT AND PLAN OF MERGER

BY AND AMONG

CHART INC.,

BISON CORP.,

AIRSEP CORPORATION,

JOSEPH L. PRIEST,

RAVINDER K. BANSAL,

AND

CHART INDUSTRIES, INC.

THIS AMENDMENT (this “Amendment”), dated as of August 30, 2012, is by and among Chart Inc., a Delaware corporation (“Parent”), Bison Corp., a New York corporation and a wholly owned subsidiary of Parent (“Merger Sub”), AirSep Corporation, a New York corporation (the “Company”), Joseph L. Priest, solely in his capacity as the Representative, for purposes of Section 4.10 only, Joseph L. Priest and Ravinder K. Bansal, and, for purposes of Section 9.14 only, Chart Industries, Inc., a Delaware corporation and direct or indirect parent of Parent (the “Ultimate Parent”).

RECITALS:

Parent, Merger Sub, Company, Representative, Joseph L. Priest, Ravinder K. Bansal, and Ultimate Parent are parties to that certain Agreement and Plan of Merger, dated July 23, 2012 (the “Agreement”).

The parties hereto desire to amend the Agreement pursuant to and in accordance with Section 9.8 of the Agreement as set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

1. Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement. References to Sections in this Amendment refer to such Sections of the Agreement.

2. Amendment. The Agreement is hereby amended as follows:

a. Section 1.2(a)(3) is hereby amended and restated in its entirety as follows:

CLI-2016195v3

a certificate, dated as of the Closing Date and executed on behalf of the Company by its Chairman and Chief Executive Officer or its President and Treasurer, certifying that attached are true and correct copies of (A) the Company’s articles of incorporation, (B) the Company’s bylaws, (C) board resolutions approving the Merger and adopting this Agreement, and (D) documentation confirming the Shareholder Approval;

b. The lead-in to Section 1.2(a)(5) is hereby amended and restated in its entirety as follows:

a certificate, dated as of the Closing Date and executed on behalf of the Company by its Chairman and Chief Executive Officer or its President and Treasurer, setting forth or accompanying the following information and certifying that the information is accurate and complete:

c. Section 1.2(a)(5)(ii) is hereby amended and restated in its entirety as follows:

the Company Indebtedness, the Purchased Indebtedness and the Excess Indebtedness as of immediately prior to the Closing, if any, in reasonable detail and separated by lender (which calculation will include the adjustment of negative cash and accounts payable as provided in Section 4.13 of the Disclosure Schedule as of such date of determination);

d. Section 1.2(a)(6) is hereby amended and restated in its entirety as follows:

the certificate, dated as of the Closing Date and executed on behalf of the Company by its Chairman and Chief Executive Officer or its President and Treasurer, that is required by Section 6.2(d);

e. Section 1.2(a)(14) is hereby amended and restated in its entirety as follows:

a schedule in the form of Schedule 9.1(a) setting forth the Closing Net Working Capital of the Company as of August 24, 2012, delivered to Parent on August 28, 2012, with the inventory amount set forth therein based on the physical inventory conducted on August 13 and 14, 2012, by the Company and Parent and rolled forward through August 24, 2012;

f. The last two sentences of Section 2.21(a) are hereby amended and restated in their entirety as follows:

The warranty reserve set forth on the Balance Sheet was calculated, and when delivered the warranty reserve set forth on the Updated Financial Information will be calculated, in a manner consistent with past practice and in accordance with

CLI-2016195v3

GAAP consistently applied. Set forth in Section 2.21(a) of the Disclosure Schedule are the warranties of the Company for each of its product lines.

g. The last sentence of Section 4.13 is hereby amended and restated in its entirety as follows:

The updated Schedule 9.1(a) provided pursuant to Section 1.2(a)(14) and the Closing adjustment to negative cash and accounts payable pursuant to Section 1.2(a)(5)(ii) shall constitute “Updated Financial Information” for purposes of this Agreement.

h. Section 6.2(d) is hereby amended and restated in its entirety as follows:

Parent will have received a certificate, dated as of the Closing Date and executed by the Chairman and Chief Executive Officer of the Company or its President and Treasurer, certifying to his knowledge as to the compliance with and satisfaction of the conditions set forth in Sections 6.2(a), (b) and (c);

i. Section 9.1 is hereby amended by deleting the definition of Closing Balance Sheet.

j. Section 9.1 is hereby further amended to amend and restate the definition of “Closing Net Working Capital” as follows:

“Closing Net Working Capital” means (A) the sum of the net accounts receivable, net inventory, prepaid expenses and long term accounts receivable of the Company, less (B) the sum of accounts payable, accrued expenses and customer prepayments of the Company, to be delivered to Parent pursuant to Section 1.2(a)(14), each as calculated in accordance with Section 1.2(a)(14) and Schedule 9.1(a) and determined in accordance with GAAP applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that were used in the preparation of the Financial Statements.

k. Section 2.4(b) of the Disclosure Schedule is hereby amended by deleting item 2 therein.

3. Binding Effect. Except to the extent expressly provided herein, the Agreement shall remain in full force and effect in accordance with its terms.

CLI-2016195v3

4. Counterparts. This Amendment may be executed in any number of counterparts, and by the different parties hereto in separate counterparts, each of which when executed will be deemed to be an original but all of which taken together will constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by telecopy or by electronic delivery in Adobe Portable Document Format or other electronic format based on common standards will be effective as delivery of a manually executed counterpart of this Amendment.

5. Miscellaneous. This Amendment shall be deemed to be a Related Agreement under the Agreement. Each of the parties hereto represents and warrants with respect to itself that (i) it has the power and authority to execute, deliver and perform its obligations under this Amendment, (ii) the execution, delivery and performance of this Amendment has been duly authorized by all requisite corporate action on the part of it, (iii) this Amendment has been duly executed and delivered by such party and, assuming due authorization, execution and delivery by the other parties hereto, represents the legal, valid and binding obligation of such party enforceable against it in accordance with its terms, subject to the effect of the General Enforceability Exceptions. Article 9 of the Agreement is incorporated herein by reference and, to the extent applicable, shall govern the terms of this Amendment.

[remainder of page intentionally left blank]

CLI-2016195v3

IN WITNESS WHEREOF, each of the undersigned have caused this Amendment to be executed individually or by their respective officers thereunto duly authorized, in each case as of the date first written above.

AIRSEP CORPORATION	CHART INC.
/s/ Ravinder K. Bansal	/s/ Michael F. Biehl
Name: Ravinder K. Bansal	Name: Michael F. Biehl
Title: Chairman & CEO	Title: Executive Vice President, Chief Financial Officer and Treasurer
JOSEPH L. PRIEST
solely in its capacity as the Representative under Section 8.9	BISON CORP.
/s/ Joseph L. Priest	/s/ Michael F. Biehl
Name: Joseph L. Priest	Name: Michael F. Biehl
Title:	Title: Executive Vice President, Chief Financial Officer and Treasurer
Solely as to Section 4.10:	Solely as to Section 9.14:
	CHART INDUSTRIES, INC.
/s/ Joseph L. Priest	/s/ Michael F. Biehl
JOSEPH L. PRIEST	Name: Michael F. Biehl
	Title: Executive Vice President, Chief Financial Officer and Treasurer
/s/ Ravinder K. Bansal
RAVINDER K. BANSAL

1063956.2

CLI-2016195v3

EX-10.1

Exhibit 10.1

Amendment No. 1 to the

Chart Industries, Inc. Amended and Restated 2009 Omnibus Equity Plan

This Amendment No. 1 (this “Amendment”) to the Chart Industries, Inc. Amended and Restated 2009 Omnibus Equity Plan (the “Plan”) is approved and adopted on this 17th day of October, 2012 (the “Effective Date”) by Chart Industries, Inc. (the “Company”).

WITNESSETH:

WHEREAS, the Plan became effective on May 24, 2012, the date on which the stockholders of the Company approved the Plan;

WHEREAS, under Section 14.1 of the Plan, the Board of Directors may amend the Plan at any time.

NOW, THEREFORE, as of the Effective Date, the Plan is hereby amended as follows:

1. Section 2.2 of the Plan is hereby deleted in its entirety and replaced with the following:

“2.2 Delegation of Duties. The Committee may delegate ministerial duties to any other person or persons, and it may employ attorneys, consultants, accountants or other professional advisers for purposes relating to plan administration at the expense of the Company.The Committee may, by resolution, authorize a subcommittee of the Compensation Committee or another committee of the Board to do one or both of the following on the same basis as the Committee: (a) designate employees to be recipients of awards under this Plan; (b) determine the size of any such awards; provided,however, that (x) the Committee will not delegate such responsibilities to any such subcommittee or committee for awards granted to a participant who is a Section 16 Person and/or a Section 162(m) Person; (y) the resolution providing for such authorization sets forth the total number of Common Shares such subcommittee or committee may grant; and (z) the subcommittee or committee will report periodically to the Committee regarding the nature and scope of the awards granted pursuant to the authority delegated.”

2. Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to them in the Plan.

3. Except as otherwise modified in this Amendment, the Plan shall remain in full force and effect. In the event of a conflict between the terms of this Amendment and the Plan, the terms of this Amendment shall control.

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Samuel F. Thomas, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Chart Industries, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2012

    /s/ Samuel F. Thomas

Samuel F. Thomas

Chairman of the Board, Chief Executive Officer and President

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Michael F. Biehl, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Chart Industries, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2012

    /s/ Michael F. Biehl

Michael F. Biehl

Executive Vice President, Chief Financial Officer and Treasurer

EX-32.1

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Chart Industries, Inc., a Delaware corporation (the “Company"), does hereby certify, to such officer's knowledge, that:

(a) The Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.

Dated: November 1, 2012

  /s/ Samuel F. Thomas

Samuel F. Thomas

Chairman of the Board, Chief Executive Officer and President

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Chart Industries, Inc., a Delaware corporation (the “Company"), does hereby certify, to such officer's knowledge, that:

(a) The Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.

Dated: November 1, 2012

  /s/ Michael F. Biehl

Michael F. Biehl

Executive Vice President, Chief Financial Officer and Treasurer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Accumulated Other Comprehensive Income (Loss) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Change in foreign currency translation adjustments
Balance at beginning of period	$ 10,969	$ 22,166	$ 12,635	$ 14,938
Other comprehensive income, net of tax	2,299	(11,137)	633	(3,909)
Balance at end of period	13,268	11,029	13,268	11,029
Change in pension liability adjustments, net of taxes
Balance at beginning of period	(9,155)	(4,945)	(9,642)	(5,127)
Other comprehensive income, net of tax	244	91	731	273
Balance at end of period	(8,911)	(4,854)	(8,911)	(4,854)
Change in accumulated other comprehensive income (loss)
Balance at beginning of period	1,814	17,221	2,993	9,811
Other comprehensive income (loss), net of tax	2,543	(11,046)	1,364	(3,636)
Balance at end of period	$ 4,357	$ 6,175	$ 4,357	$ 6,175

XML

Basis of Preparation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Accounting Policies [Abstract]
Minimum ownership percentage of investments in affiliates required to be accounted for under the equity method	20.00%		20.00%
Maximum ownership percentage of investments in affiliates required to be accounted for under the equity method	50.00%		50.00%
Maximum maturity duration considered to be cash and cash equivalents	3 months		3 months
Minimum maturity duration of short-term, highly liquid, variable-rate instruments	3 months		3 months
Maximum maturity duration of short-term, highly liquid, variable-rate instruments	6 months		6 months
Components of inventory:
Raw materials and supplies	$ 84,686		$ 84,686		$ 64,832
Work in process	46,719		46,719		36,045
Finished goods	73,374		73,374		48,945
Inventories, net	204,779		204,779		149,822
Changes in the Company's consolidated warranty reserve:
Beginning balance	11,248	12,849	13,181	13,372
Warranty expense	2,741	1,631	6,343	5,233
Warranty usage	(3,722)	(1,949)	(9,257)	(6,074)
Acquired warranty reserves	18,779	817	18,779	817
Ending balance	$ 29,046	$ 13,348	$ 29,046	$ 13,348

XML

Reportable Segments (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Segment Reporting Information [Line Items]
Assets	$ 1,323,236		$ 1,323,236		$ 1,174,475
Sales	254,249	211,311	710,294	574,950
Operating Income (Loss)	32,032	29,043	88,976	64,839
Energy & Chemicals [Member]
Segment Reporting Information [Line Items]
Assets	237,381		237,381		203,067
Sales	82,968	57,777	228,921	149,414
Operating Income (Loss)	17,057	12,584	44,785	21,941
Distribution & Storage [Member]
Segment Reporting Information [Line Items]
Assets	580,284		580,284		556,688
Sales	117,752	100,911	336,278	275,966
Operating Income (Loss)	19,948	16,109	54,447	44,731
BioMedical [Member]
Segment Reporting Information [Line Items]
Assets	456,384		456,384		226,729
Sales	53,529	52,623	145,095	149,570
Operating Income (Loss)	7,051	8,548	25,498	24,218
Corporate [Member]
Segment Reporting Information [Line Items]
Assets	49,187		49,187		187,991
Sales	0	0	0	0
Operating Income (Loss)	$ (12,024)	$ (8,198)	$ (35,754)	$ (26,051)

XML

Restructuring Activities

9 Months Ended

Sep. 30, 2012

Restructuring and Related Activities [Abstract]

Restructuring Activities

Restructuring Activities

The Company recorded $359 and $390 for the three and nine months ended September 30, 2012, respectively, in restructuring costs for employee separation benefits primarily related to the integration of SeQual Technologies Inc. These charges were recorded in cost of sales ($318 and $349 for the three and nine months ended September 30, 2012, respectively) and selling, general and administrative expenses ($41 for both the three and nine months ended September 30, 2012).

The Company recorded $696 and $2,905 for the three and nine months ended September 30, 2011, respectively, in restructuring costs related to the closure of the Plainfield, Indiana BioMedical manufacturing facility. The Company also recorded $372 and $1,353 for the three and nine months ended September 30, 2011, respectively, for employee separation benefits related to the integration of SeQual Technologies, Inc. An additional $733 was recorded for the nine months ended September 30, 2011 related to various restructuring efforts across the Company. These charges were recorded in cost of sales ($696 and $1,661 for the three and nine months ended September 30, 2011, respectively) and selling, general and administrative expenses ($372 and $2,114 for the three and nine months ended September 30, 2011, respectively), and a $1,216 loss on disposal of assets for the nine months ended September 30, 2011.

The restructuring liability is recorded in other current liabilities on the condensed consolidated balance sheets. The following tables summarize the Company’s restructuring activities for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2012	$	—	$	6		$	225		$	—	$	231
Restructuring charges	—		—			359			—		359
Cash payments and other	—		(4		)	(329		)	—		(333		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2012	$	—	$	115		$	998		$	—	$	1,113
Restructuring charges	—		—			390			—		390
Cash payments and other	—		(113		)	(1,133		)	—		(1,246		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2011	$	—	$	157		$	1,966		$	—	$	2,123
Restructuring charges	—		—			1,068			—		1,068
Cash payments and other	—		(43		)	(1,352		)	—		(1,395		)
Balance as of September 30, 2011	$	—	$	114		$	1,682		$	—	$	1,796

	Nine Months Ended September 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of January 1, 2011	$	103		$	388		$	2,088		$	—		$	2,579
Restructuring charges	—			26			4,528			437			4,991
Loss on disposal of assets	—			—			(1,216		)	—			(1,216		)
Cash payments and other	(103		)	(300		)	(3,718		)	(437		)	(4,558		)
Balance as of September 30, 2011	$	—		$	114		$	1,682		$	—		$	1,796

XML

Fair Value Measurements (Details) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended																								3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 Selling, general and administrative expense [Member] USD ($)	Sep. 30, 2012 Fair Value, Inputs, Level 2 [Member] USD ($)	Dec. 31, 2011 Fair Value, Inputs, Level 2 [Member] USD ($)	Sep. 30, 2012 Fair Value, Inputs, Level 3 [Member] USD ($)	Dec. 31, 2011 Fair Value, Inputs, Level 3 [Member] USD ($)	Sep. 30, 2012 Euros against the U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] EUR (€)	Dec. 31, 2011 Euros against the U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] EUR (€)	Sep. 30, 2012 Euros against the Czech koruna [Member] Fair Value, Inputs, Level 2 [Member] EUR (€)	Dec. 31, 2011 Euros against the Czech koruna [Member] Fair Value, Inputs, Level 2 [Member] EUR (€)	Sep. 30, 2012 Japanese yen against U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] JPY (¥)	Dec. 31, 2011 Japanese yen against U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] JPY (¥)	Sep. 30, 2012 Austrailian dollars against the U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] AUD	Sep. 30, 2012 British pounds against the U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] GBP (£)	Dec. 31, 2011 British pounds against the U.S. dollar [Member] Fair Value, Inputs, Level 2 [Member] GBP (£)	Dec. 31, 2011 Norwegian kroner against euro [Member] Fair Value, Inputs, Level 2 [Member] NOK	Sep. 30, 2012 British pounds against the Czech koruna [Member] Fair Value, Inputs, Level 2 [Member] GBP (£)	Sep. 30, 2012 U.S. Dollars Against Czeck Koruna [Member] Fair Value, Inputs, Level 2 [Member] USD ($)	Sep. 30, 2012 British pounds against the euro [Member] Fair Value, Inputs, Level 2 [Member] GBP (£)	Dec. 31, 2011 Czech koruna against U.S. Dollar [Member] Fair Value, Inputs, Level 2 [Member] CZK	Dec. 31, 2011 Czech koruna against Euro [Member] Fair Value, Inputs, Level 2 [Member] CZK	Sep. 30, 2012 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] Fair Value, Inputs, Level 1 [Member] Maximum [Member]	Dec. 31, 2011 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] Fair Value, Inputs, Level 1 [Member] Maximum [Member]	Sep. 30, 2012 BioMedical [Member] USD ($)	Sep. 30, 2012 BioMedical [Member] USD ($)	Sep. 30, 2012 BioMedical [Member] Maximum [Member] USD ($)	Sep. 30, 2012 Distribution & Storage [Member] USD ($)	Sep. 30, 2012 Distribution & Storage [Member] USD ($)	Apr. 25, 2012 Revolving Line of Credit [Member] Amended Revolver [Member] USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maximum Amount Of Permitable Subsidiary Borrowings																																$ 50,000
Gain (loss) on foreign currency hedges	(1,068)	1,379	(1,619)	1,943
Forward currency contract amounts										48,700	11,500	2,280	3,340	60,000	130,000	800	700	250	3,000	510	980	200	4,700	17,500
Fair value of derivative liability						1,655	191
Fair value of derivative assets						11	489
Percent that the fair value of the liability component of the Convertible Notes exceeded it's carrying value																									131.00%	108.00%
Fair value of the contingent consideration								1,990	7,067
Increase (decrease) in fair value of the contingent consideration recorded in earnings					(5,077)																						73	(4,236)		15	459
Payment of contingent consideration			(1,300)	(1,300)																							(1,300)
Change in amount of contingent consideration obligation			4,620	0
Potential cash payment of contingent consideration																													$ 3,000

XML

Basis of Preparation - Stock-based Compensation (Details) (USD $) Share data in Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,530,000	$ 1,407,000	$ 5,711,000	$ 4,208,000
Stock-based compensation weighted average period (in years)			1 year 11 months 1 day
Stock-based compensation expected to be recognized over the wieghted average period	8,075,000		8,075,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Stock options granted in period (in shares)			104
Stock options exercised in period (in shares)			286
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Other stock-based compensation grants in period (in shares)			31
Performance Based Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Other stock-based compensation grants in period (in shares)			15
Leveraged Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Other stock-based compensation grants in period (in shares)			18
Non-employee stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Other stock-based compensation grants in period (in shares)			4
Share-based Compensation Arrangement by Share-based Payment Award,Fair Value	$ 274,000		$ 274,000

XML

Debt and Credit Arrangements (Details) Share data in Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended														9 Months Ended				3 Months Ended	9 Months Ended							9 Months Ended				12 Months Ended
	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Dec. 31, 2011 USD ($)	Aug. 31, 2011	Sep. 30, 2012 Chart Ferox [Member] Facility 2 [Member]	Sep. 30, 2012 Line of Credit [Member] Chart Ferox [Member] CZK creditfacilities	Sep. 30, 2012 Line of Credit [Member] Chart Ferox [Member] Facility 1 [Member] USD ($)	Oct. 31, 2011 Foreign Facilities [Member] Bonding/Guarantee Facility [Member] Chart Cryogenic Engineering Systems Co., Ltd. [Member] CNY	Oct. 31, 2011 Foreign Facilities [Member] Overdraft Facility [Member] Chart Cryogenic Engineering Systems Co., Ltd. [Member] CNY	Sep. 30, 2012 Foreign Facilities [Member] Line of Credit [Member] Chart Cryogenic Engineering Systems Co., Ltd. [Member] USD ($)	Oct. 31, 2011 Foreign Facilities [Member] Line of Credit [Member] Chart Cryogenic Engineering Systems Co., Ltd. [Member] CNY	Sep. 30, 2012 Amended Revolver [Member] Revolving Line of Credit [Member] USD ($)	Apr. 25, 2012 Amended Revolver [Member] Revolving Line of Credit [Member] USD ($)	May 18, 2010 Term Loan [Member] Senior Term Loan, Due 2015 [Member] USD ($)	Sep. 30, 2012 Term Loan [Member] Senior Term Loan, Due 2017 [Member] USD ($)	Apr. 25, 2012 Term Loan [Member] Senior Term Loan, Due 2017 [Member] USD ($)	Apr. 25, 2012 Term Loan [Member] Senior Term Loan, Due 2017 [Member] Percentage in Excess of Federal Funds Effective Rate [Member]	May 18, 2010 Revolving Line of Credit [Member] Revolver [Member] USD ($)	Sep. 30, 2012 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] USD ($)	Sep. 30, 2012 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] USD ($)	Sep. 30, 2011 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] USD ($)	Dec. 31, 2011 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] USD ($)	Aug. 31, 2011 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] USD ($)	Sep. 30, 2012 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] Additional Paid-in Capital [Member] USD ($)	Aug. 31, 2011 Convertible Notes Payable [Member] Convertible Notes, Due 2018 [Member] Carrying Amount, Deferred Financing Fees [Member] USD ($)	Apr. 25, 2012 Line of Credit [Member] USD ($)	Sep. 30, 2012 Line of Credit [Member] Amended Senior Credit Facility [Member]	Apr. 25, 2012 Line of Credit [Member] Amended Senior Credit Facility [Member] USD ($) Y	Sep. 30, 2012 Line of Credit [Member] Senior Credit Facility [Member]	May 18, 2010 Line of Credit [Member] Senior Credit Facility [Member] USD ($) Y	Dec. 31, 2011 Subordinated Debt [Member] Subordinated Notes, Due 2015 [Member] USD ($)	Oct. 17, 2011 Subordinated Debt [Member] Subordinated Notes, Due 2015 [Member] USD ($)
Debt Instrument [Line Items]
Stated interest rate																									2.00%
Aggregate principal of amount of debt																									$ 250,000,000									$ 163,175,000
Proceeds from issuance of debt																									242,700,000
Minimum trading days required during thrirty consecutive trading days where last reported sales price is at least 130 percent of conversion price						20 days
Minimum percentage of conversion price of Convertible Notes on each trading day																									130.00%
Maximum days after any five trading day period in which trading price was less than 97 percent of last reported sale price of Common Stock times conversion rate						5 days
Convertible Notes principal amount denominator for trading price																									1,000
Maximum allowable percentage of the product of the last reported sale price of Common Stock and conversion rate for Convertible Notes Payable																									97.00%
Number of common shares convertible (shares of common stock per $1,000 principal amount of Convertible Notes)																									14.4865
Conversion price per share																									$ 69.03
Percent of the principal amount of the Convertible Notes plus accrued interest to be purchased by the Company subject to Company undergoing a fundamental change																									100.00%
Minimum holding percentage of convertible notes payable required to declare Convertible Notes to be due and payable in events of default																									25.00%
Percent of Convertible Notes declarable as due and payable in certain events of default																									100.00%
Number of shares of convertible debt hedged and capped call																									3,622
Payment for call options related to convertible notes			0	66,486,000																			66,486,000
Initial cap price of the call transactions and the strike price of warrant transactions (per share)																									84.96
Proceeds from issuance of warrants			0	48,848,000																			48,848,000
Net cost of Convertible Note hedge and all capped transactions																							17,638,000
Liability component of Convertible Notes before present value of equity component																									170,885,000
Percentage used as debt rate for present value of cash flows																									7.90%
Interest expense for the Convertible Notes																					3,549,000	10,514,000	2,254,000
Debt instrument interest expense excluding non-cash accretion expense																					1,250,000	3,750,000	833,000
Interest accretion of Convertible Notes discount																					2,299,000	6,764,000	1,421,000
Carrying amount of deferred financing fees	1,445,000		1,445,000																						7,277,000	2,303,000	4,974,000
Amortization of debt issuance costs	326,000	445,000	1,203,000	1,094,000																	178,000	533,000
Components of Convertible Notes:
Principal balance of the liability component																					250,000,000	250,000,000		250,000,000
Unamortized discount																					(68,735,000)	(68,735,000)		(75,526,000)
Carrying value of liability component																					181,265,000	181,265,000		174,474,000
Equity component, net of deferred taxes																					75,826,000	75,826,000		75,502,000	79,115,000
Number of years to maturity, senior credit facility (in years)																														5		5
Maximum borrowing capacity of line of credit facility								175,000,000		30,000,000	10,000,000		60,000,000		300,000,000	65,000,000		75,000,000		135,000,000										375,000,000		200,000,000
Gross amount of long-term debt																	73,125,000
Line of Credit Facility, Amount Outstanding														18,387,000
Sub-limit for issuance of swingline loans															25,000,000					25,000,000
Sub-limit for letters of credit															100,000,000					50,000,000
Maximum amount for foreign currency denominated letters of credit and borrowings															50,000,000					40,000,000
Maximum Amount Of Permitable Subsidiary Borrowings															50,000,000					40,000,000
Amount of expansion option to increase the aggregate principal amount of the Term loan or Revolving Credit Facility																												150,000,000
Duration of time extension under the terms of the Restated Credit Facility																													2 years
Initial percentage of Term Loan payable quarterly due to Restated Credit Facility																		5.00%
Initial duration of quarterly payments on Term Loan under the terms of the Restated Credit Facility																	3 years
Final percentage of Term Loan payable quarterly due to Restated Credit Facility																		10.00%
Final duration of quarterly payments on Term Loan under the terms of the Restated Credit Facility																	2 years
Maximum net debt to EBITDA ratio used as a significant financial covenant for the Restated Credit Facility																														3.25
Minimum interest coverage to EBITDA ratio used as a significant financial covenant for the Restated Credit Facility																														3
Amount of letters of credit outstanding														26,422,000
Line of Credit Facility, Remaining Borrowing Capacity														255,191,000
Short-term Debt, Weighted Average Interest Rate														4.25%
Maximum percentage of capital stock guaranteed by Company's material Non-U.S. Subsidiaries for obligations under the Senior Credit Facility																															65.00%
Subordinated notes redemption price percentage of principal																																		103.042%
Redemption price of Subordinated Notes principal amount plus accrued and upaid interest																																		175,600,000
Call premium in conjunction with redemption of Subordinated Notes																																		4,964,000
Deferred financing fees written off due to refinancing			232,000																														2,969,000
Revolving line of credit time to maturity	12 months		12 months
Short-term debt	23,157,000		23,157,000		4,758,000							4,770,000
Number of credit facilities maintained by Chart Ferox								2
Letter of credit and guarantee fees percentage of face amount for maturities up to one year									0.70%
Letter of credit and guarantee fees percentage of face amount for maturities between one and three years									0.80%
Letter of credit and guarantee fees percentage of face amount for maturities between three and five years									1.20%
Letter of credit and guarantee fees percentage of face amount for all maturities							0.70%
Bank guarantees supported by credit facilities									$ 897,000
Debt Instrument, Basis Spread on Variable Rate																			0.50%

XML

Restructuring Activities (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Restructuring Cost and Reserve [Line Items]
Restructuring cost		$ 696		$ 2,905
Summary of restructuring activities
Beginning balance	231	2,123	1,113	2,579
Restructuring charges	359	1,068	390	4,991
Loss on disposal of assets				(1,216)
Cash payments and other	(333)	(1,395)	(1,246)	(4,558)
Ending balance	257	1,796	257	1,796
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost	359	372	390	1,353
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost				733
Energy & Chemicals [Member]
Summary of restructuring activities
Beginning balance	0	0	0	103
Restructuring charges	0	0	0	0
Loss on disposal of assets				0
Cash payments and other	0	0	0	(103)
Ending balance	0	0	0	0
Distribution & Storage [Member]
Summary of restructuring activities
Beginning balance	6	157	115	388
Restructuring charges	0	0	0	26
Loss on disposal of assets				0
Cash payments and other	(4)	(43)	(113)	(300)
Ending balance	2	114	2	114
BioMedical [Member]
Summary of restructuring activities
Beginning balance	225	1,966	998	2,088
Restructuring charges	359	1,068	390	4,528
Loss on disposal of assets		(1,216)		(1,216)
Cash payments and other	(329)	(1,352)	(1,133)	(3,718)
Ending balance	255	1,682	255	1,682
Corporate [Member]
Summary of restructuring activities
Beginning balance	0	0	0	0
Restructuring charges	0	0	0	437
Loss on disposal of assets				0
Cash payments and other	0	0	0	(437)
Ending balance	0	0	0	0
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost	318	696	349	1,661
Selling, general and administrative expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost		$ 372	$ 41	$ 2,114

XML

Debt and Credit Arrangements

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Debt and Credit Arrangements

Debt and Credit Arrangements

In August 2011, the Company issued Convertible Notes in the aggregate principal amount of $250,000 in an offering registered under the Securities Act of 1933, as amended. The net proceeds from the offering were approximately $242,700 after deducting the underwriters’ discount and offering expenses. The Convertible Notes bear interest at a fixed rate of 2.00% per year, payable semiannually in arrears on February 1 and August 1 of each year which began on February 1, 2012. The Convertible Notes mature on August 1, 2018.

The Convertible Notes are senior subordinated unsecured obligations of the Company and are not guaranteed by any of the Company’s subsidiaries. The Convertible Notes are subordinated in right of payment to the Company’s existing and future senior indebtedness, including indebtedness under the Company’s existing credit agreement, and rank equally in right of payment with any future senior subordinated debt. The Convertible Notes rank senior in right of payment to the Company’s future subordinated debt.

Prior to May 1, 2018, the Convertible Notes will be convertible at the option of the holders thereof only under the following circumstances: (1) during any fiscal quarter commencing after September 30, 2011 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price for the Convertible Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “Measurement Period”) in which, as determined following a request by a holder of Convertible Notes as provided in the bond indenture (the “Indenture”), the trading price per $1,000 principal amount of Convertible Notes for each trading day of such Measurement Period was less than 97% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate for the Convertible Notes on each such trading day; or (3) upon the occurrence of specified corporate events pursuant to the terms of the Indenture. On or after May 1, 2018, until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders of the Convertible Notes may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted. It is the Company’s intention to settle any excess conversion value in shares of the Company’s common stock.

The conversion rate will initially equal 14.4865 shares of the Company’s common stock per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $69.03 per share. The conversion rate will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of a make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate for a holder that converts its Convertible Notes in connection with such make-whole fundamental change. The Company may not redeem the Convertible Notes prior to maturity. No sinking fund will be provided for the Convertible Notes. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to purchase

the Convertible Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the Convertible Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. In certain Events of Default, as defined in the Indenture, the Trustee by notice to the Company, or the holders of at least 25% in principal amount of then outstanding Convertible Notes by notice to the Company and to the Trustee, may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all then outstanding Convertible Notes to be due and payable. Upon such a declaration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

As of September 30, 2012, the Convertible Notes were not subject to conversion.

In connection with the issuance of the Convertible Notes, the Company entered into privately-negotiated convertible note hedge and capped call transactions with affiliates of certain of the underwriters (the “Option Counterparties”). The convertible note hedge and capped call transactions relate to, collectively, 3,622 shares, which represents the number of shares of the Company’s common stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes. These convertible note hedge and capped call transactions are expected to reduce the potential dilution with respect to the Company’s common stock upon conversion of the Convertible Notes and/or reduce the Company’s exposure to potential cash or stock payments that may be required upon conversion of the Convertible Notes, except, in the case of the capped call transactions, to the extent that the market price per share of the Company’s common stock exceeds the cap price of the capped call transactions. The convertible note hedge and capped call transactions, which cost the Company $66,486, were recorded as a reduction of additional paid-in-capital.

The Company also entered into separate warrant transactions with the Option Counterparties initially relating to the number of shares of the Company’s common stock underlying the convertible note hedge transactions, subject to customary anti-dilution adjustments. The warrant transactions will have a dilutive effect with respect to the Company’s common stock to the extent that the price per share of the Company common stock exceeds the strike price of the warrants unless the Company elects, subject to certain conditions, to settle the warrants in cash. These warrants were exercisable as of the issuance date of the Convertible Notes. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. Proceeds received from the issuance of the warrants totaled approximately $48,848 and were recorded as an addition to additional paid-in-capital. The net cost of the convertible note hedge and capped call transactions, taking into account the proceeds from the issuance of the warrants, was approximately $17,638. In accordance with ASC 815, contracts are initially classified as equity if (1) the contract requires physical settlement or net-share settlement, or (2) the contract gives the entity a choice of net-cash settlement in its own shares (physical settlement or net-share settlement). The Company concluded that the settlement terms of the convertible note hedge, capped call and warrant transactions permit net-share settlement. As such, the convertible note hedge, capped call and warrant transactions were recorded in equity.

At the issuance of the Convertible Notes, the Company bifurcated the $250,000 principal balance of the Convertible Notes into a liability component of $170,885 which was recorded as long-term debt and an equity component of $79,115 which was recorded as additional paid-in-capital. The liability component was recognized at the present value of its associated cash flows using a 7.9% straight-debt rate which represents the Company’s interest rate for similar debt instruments without a conversion feature and is being accreted to interest expense over the term of the Convertible Notes. For the three and nine months ended September 30, 2012, interest expense for the Convertible Notes was $3,549 and $10,514, respectively, which included $1,250 and $3,750 of contractual 2.00% coupon interest, respectively, and $2,299 and $6,764 of non-cash interest accretion expense related to the carrying value of the Convertible Notes, respectively. For both the three and nine months ended September 30, 2011, interest expense for the Convertible Notes was $2,254, which included $833 and $1,421 in coupon interest and interest accretion expense, respectively.

In accordance with ASC 470-20, which requires issuers to separately account for the liability and equity components of convertible debt instruments that may be settled in cash upon conversion, the Company allocated debt issuance costs to the liability and equity components in proportion to their allocated value. Debt issuance costs were $7,277 with $2,303 recorded as a reduction in additional paid-in-capital. This balance of $4,974 is being amortized over the term of the Convertible Notes. For the three and nine months ended September 30, 2012, total expense associated with the amortization of debt issuance costs was $178 and $533, respectively.

The following table represents the principal balance, the unamortized discount and the net carrying amount of the liability component and the carrying amount of the equity component of the Convertible Notes:

	September 30, 2012			December 31, 2011
Principal balance of liability component	$	250,000		$	250,000
Unamortized discount	(68,735		)	(75,526		)
Carrying amount of liability component	$	181,265		$	174,474
Equity component, net of deferred taxes	$	75,826		$	75,502

The Company had a five-year $200,000 senior credit facility (the “Senior Credit Facility”) until April 25, 2012, which consisted of a $65,000 term loan and a $135,000 revolving credit facility (the “Revolver”) with a scheduled maturity date of May 18, 2015. The Revolver included a $25,000 sub-limit for the issuance of swingline loans and a $50,000 sub-limit to be used for letters of credit. There was a foreign currency limit of $40,000 under the Revolver which could be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permitted borrowings up to $40,000 under the Revolver made by the Company’s wholly-owned subsidiary, Chart Industries Luxembourg S.à r.l. The Senior Credit Facility was amended and restated on April 25, 2012 with a five-year $375,000 senior credit facility (the "Restated Credit Facility"), which consists of a $75,000 term loan (the "Term Loan") and a $300,000 revolving credit facility (the "Revolving Credit Facility"), and the maturity date was extended two years until April 25, 2017. The Revolving Credit Facility includes a $25,000 sub-limit for the issuance of swingline loans and a $100,000 sub-limit to be used for letters of credit. There is a foreign currency limit of $50,000 under the Revolving Credit Facility which could be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permits borrowings up to $50,000 under the Revolver made by the Company’s wholly-owned subsidiary, Chart Industries Luxembourg S.à r.l. The Company recorded $1,445 in deferred financing costs related to the Restated Credit Facility which is being amortized over the five-year term of the loan. In accordance with loan modification accounting guidance, the Company recorded a $232 charge to write off a portion of the remaining deferred financing fees associated with the former Senior Credit Facility. The Restated Credit Facility also includes an expansion option permitting the Company to add up to an aggregate of $150,000 in term loans or revolving credit commitments from its existing and potential new lenders. Loans under the Restated Credit Facility bear interest, at the applicable Borrower's election, at either LIBOR or the greatest of (a) the JPMorgan prime rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% or (c) the Adjusted LIBOR Rate (as defined in the Restated Credit Facility) for a one month interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1%, plus a margin that varies with the Company's net debt to EBITDA ratio. Under the terms of the Restated Credit Facility, 5% of the $75,000 Term Loan is payable annually in quarterly installments over the first three years, 10% is payable annually in quarterly installments over the final two years, and the remaining balance is due on April 25, 2017.

The Restated Credit Facility contains a number of customary covenants, including but not limited to restrictions on the Company’s ability to incur additional indebtedness, create liens or other encumbrances, sell assets, enter into sale and lease-back transactions, make certain payments, investments, loans, advances or guarantees, make acquisitions and engage in mergers or consolidations, pay dividends or distributions, and make capital expenditures. Significant financial covenants for the Restated Credit Facility include a maximum net debt to EBITDA ratio of 3.25 and a minimum interest coverage to EBITDA ratio of 3.0, which are the same limits that applied under the prior Senior Credit Facility. As of September 30, 2012, the Company was in compliance with all covenants. As of September 30, 2012, there was $73,125 outstanding under the Term Loan, $18,387 of borrowings outstanding under the Revolving Credit Facility (average interest rate of 4.25%), and $26,422 in letters of credit issued. As of September 30, 2012, availability under the Revolving Credit Facility was $255,191. The obligations under the Restated Credit Facility are guaranteed by the Company and substantially all of its U.S. subsidiaries and secured by substantially all of the assets of the Company’s U.S. subsidiaries and 65% of the capital stock of the Company’s material non-U.S. subsidiaries (as defined by the Restated Credit Facility) that are owned by U.S. subsidiaries.

On October 17, 2011, the Company redeemed the $163,175 outstanding principal amount of its 9-1/8% Subordinated Notes which were due in 2015. The redemption price was 103.042% of the principal amount plus accrued and unpaid interest to, but not including, the redemption date, which totaled approximately $175,600. In conjunction with the redemption of the Subordinated Notes, the Company recorded a $4,964 call premium and additional amortization of $2,969 for the write-off of the remaining deferred financing fees related to the Subordinated Notes.

In October 2011, Chart Cryogenic Engineering Systems (Changzhou) Co., Ltd., a wholly-owned subsidiary of the Company, entered into three separate banking facilities (the "Foreign Facilities") which include a bonding/guarantee facility, a revolving line of credit, and an overdraft facility with 30,000, 60,000, and 10,000 Chinese yuan (in thousands) in borrowing capacity, respectively. The Foreign Facilities are guaranteed by the Company. The revolving line of credit has a time to maturity of up to twelve months and was recorded as short-term debt at the date of issuance. As of September 30, 2012, the Company had $4,770 of borrowings outstanding under the revolving line of credit. As of September 30, 2012, there were no amounts outstanding under the overdraft facility or the bonding/guarantee facility.

Chart Ferox, a.s. (Ferox), a wholly-owned subsidiary of the Company, maintains secured credit facilities with capacity of up to 175,000 thousand Czech koruna. Ferox maintains two separate facilities. Both of the facilities allow Ferox to request issuance of bank guarantees and letters of credit. None of the facilities allow revolving credit borrowings, including overdraft protection. Under this first facility, Ferox must pay letter of credit and guarantee fees equal to: (i) 0.70% p.a. on the face amount of each guarantee or letter of credit for maturities of up to 1 year, (ii) 0.80% p.a. for maturities between 1 and 3 years, and (iii) 1.20% p.a. for maturities between 3 and 5 years. Under the second facility, Ferox must pay letter of credit and guarantee fees equal to 0.70% p.a. on the face amount of each guarantee or letter of credit. Ferox is not required to pay a commitment fee to the lender under the second facility. Ferox’s land, buildings and accounts receivable secure the credit facilities. As of September 30, 2012, there were bank guarantees of $897 supported by the Ferox credit facilities.

XML

Earnings Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Calculations of net income per share of common stock
Net income attributable to Chart Industries, Inc.	$ 18,516	$ 17,540	$ 50,535	$ 35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$ 0.62	$ 0.60	$ 1.70	$ 1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$ 0.61	$ 0.59	$ 1.68	$ 1.19
Weighted average number of common shares outstanding – basic	29,839	29,288	29,743	29,088
Incremental Common Shares Attributable to Share-based Payment Arrangements	391	678	412	783
Incremental Common Shares Attributable to Conversion of Debt Securities	13	0	13	0
Weighted average number of common shares outstanding – diluted	30,243	29,966	30,168	29,871
Stock Options [Member]
Calculations of net income per share of common stock
Anti-dilutive stock options exluded from total shares-diluted (in shares)	116	148	110	97

XML

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 105,775	$ 256,861
Accounts receivable, less allowances of $4,402 and $2,360	181,170	131,904
Inventories, net	204,779	149,822
Unbilled contract revenue	25,462	25,247
Prepaid expenses	13,403	7,088
Deferred income taxes	29,323	14,004
Other current assets	11,959	12,703
Total Current Assets	571,871	597,629
Property, plant and equipment, net	158,672	137,301
Goodwill	387,242	288,770
Identifiable intangible assets, net	194,631	140,553
Other assets, net	10,820	10,222
TOTAL ASSETS	1,323,236	1,174,475
Current Liabilities
Accounts payable	85,416	84,297
Customer advances and billings in excess of contract revenue	106,438	102,996
Employee-related Liabilities, Current	27,228	29,108
Current portion of warranty reserve	20,187	13,181
Short-term debt	23,157	4,758
Current portion of long-term debt	3,750	6,500
Other current liabilities	28,170	24,653
Total Current Liabilities	294,346	265,493
Long-term debt	250,640	223,224
Long-term deferred tax liability, net	68,425	43,945
Accrued pension liabilities	13,841	15,905
Other long-term liabilities	17,002	12,357
Chart Industries’ shareholders’ equity:
Common stock, par value $.01 per share – 150,000,000 shares authorized, 30,000,390 and 29,612,684 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	300	296
Additional paid-in capital	345,707	333,034
Retained earnings	325,251	274,716
Accumulated other comprehensive income	4,357	2,993
Total Chart Industries, Inc. shareholders’ equity	675,615	611,039
Noncontrolling interest	3,367	2,512
Total equity	678,982	613,551
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,323,236	$ 1,174,475

XML

Basis of Preparation

9 Months Ended

Sep. 30, 2012

Accounting Policies [Abstract]

Basis of Preparation

Basis of Preparation

The accompanying unaudited condensed consolidated financial statements of Chart Industries, Inc. and its subsidiaries (the “Company” or “Chart”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for annual financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.

Principles of Consolidation: The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation. Investments in affiliates where the Company’s ownership is between 20 percent and 50 percent, or where the Company does not have control, but has the ability to exercise significant influence over operations or financial policy, are accounted for under the equity method.

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Reclassifications: Certain reclassifications have been made to the 2011 condensed consolidated balance sheet and condensed consolidated cash flow statement in order to conform to the 2012 presentation.

Nature of Operations: The Company is a leading global manufacturer of standard and custom-engineered products and systems serving a wide variety of low-temperature and cryogenic applications. The Company has developed an expertise in medical respiratory equipment and cryogenic systems and equipment, which operate at low temperatures sometimes approaching absolute zero. The majority of the Company’s products, including vacuum insulated containment vessels, heat exchangers, cold boxes and other cryogenic components, are used throughout the liquid-gas supply chain for the purification, liquefaction, distribution, storage and end-use of industrial gases and hydrocarbons. The Company has domestic operations located across the United States, including the principal executive offices located in Ohio, and an international presence in Asia, Australia and Europe.

Cost of Sales: Manufacturing expenses associated with sales are included in cost of sales. Cost of sales includes all materials, direct and indirect labor, inbound freight, purchasing and receiving, inspection, internal transfers and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs, manufacturing engineering, project management and depreciation expense for assets used in the manufacturing process are included in cost of sales.

Selling, General and Administrative Costs (SG&A): SG&A includes selling, marketing, customer service, product management, design engineering, and other administrative costs not directly supporting the manufacturing process as well as depreciation and amortization expense associated with non-manufacturing assets. In addition, SG&A includes corporate operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and share-based compensation expense.

Cash and Cash Equivalents: The Company considers all investments with an initial maturity of three months or less when purchased to be cash equivalents. The December 31, 2011 balances include money market investments, certificates of deposit, and commercial paper. As of September 30, 2012, Chart Cryogenic Distribution Equipment (Changzhou) Company Limited, a joint venture of the Company, and Chart Cryogenic Engineering Systems (Changzhou) Company Limited held $1,055 and $844 in restricted cash on deposit, respectively, to cover guarantees.

Short-Term Investments: From time to time, the Company invests in short-term, highly liquid, variable rate instruments, which have stated maturities of greater than three months but less than six months. These short-term investments are recorded at cost which approximates fair value. The Company has determined that its investment securities are available and intended for use in current operations and, accordingly, classifies investment securities as current assets. There were no short term investments at September 30, 2012 or December 31, 2011.

Inventories: Inventories are stated at the lower of cost or market with cost being determined by the first-in, first-out (“FIFO”) method. The components of inventory are as follows:

	September 30, 2012		December 31, 2011
Raw materials and supplies	$	84,686	$	64,832
Work in process	46,719		36,045
Finished goods	73,374		48,945
	$	204,779	$	149,822

Revenue Recognition: For the majority of the Company’s products, revenue is recognized when products are shipped, title has transferred and collection is reasonably assured. For these products, there is also persuasive evidence of an arrangement and the selling price to the buyer is fixed or determinable. For brazed aluminum heat exchangers, cold boxes, liquefied natural gas fueling stations and engineered tanks, the Company uses the percentage of completion method of accounting. Earned revenue is based on the percentage of incurred costs to date compared to total estimated costs at completion after giving effect to the most current estimates. The cumulative impact of revisions in total cost estimates during the progress of work is reflected in the period in which these changes become known. Earned revenue reflects the original contract price adjusted for agreed upon claims and change orders, if any. Losses expected to be incurred on contracts in process, after consideration of estimated minimum recoveries from claims and change orders, are charged to operations as soon as such losses are known. Pre-contract costs relate primarily to salaries and benefits incurred to support the selling effort and are expensed as incurred. Change orders resulting in additional revenue and profit are recognized upon approval by the customer based on the percentage of incurred costs to date compared to total estimated costs at completion. Certain contracts include incentive-fee arrangements. The incentive fees in such contracts can be based on a variety of factors but the most common are the achievement of target completion dates, target costs, and/or other performance criteria. Incentive-fee revenue is not recognized until it is earned. Timing of amounts billed on contracts varies from contract to contract and could cause a significant variation in working capital requirements. The Company reports sales net of tax assessed by qualifying governmental authorities.

Product Warranties: The Company provides product warranties with varying terms and durations for the majority of its products. The Company calculates its warranty reserve by considering historical warranty experience and specifically identified warranty issues. The Company records warranty expense in cost of sales. Product warranty claims not expected to occur within one year are recorded in other long-term liabilities in the condensed consolidated balance sheets. Actual experience could differ from the amounts estimated requiring adjustments to the liability in future periods. The changes in the Company’s consolidated warranty reserve during the three and nine months ended September 30, 2012 and 2011 are as follows (see Note G for further details on the acquired warranty reserves):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Beginning balance	$	11,248		$	12,849		$	13,181		$	13,372
Warranty expense	2,741			1,631			6,343			5,233
Warranty usage	(3,722		)	(1,949		)	(9,257		)	(6,074		)
Acquired warranty reserves	18,779			817			18,779			817
Ending balance	$	29,046		$	13,348		$	29,046		$	13,348

Goodwill and Other Intangible Assets: The Company does not amortize goodwill or other indefinite-lived intangible assets, but reviews them at least annually for impairment, and on an interim basis if necessary, using a measurement date of October 1st. The Company amortizes intangible assets that have finite lives over their useful lives.

With respect to goodwill, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The reporting units are the same as our operating segments, which are also the reportable segments: Energy & Chemicals, Distribution & Storage, and BioMedical. The Company first evaluates relevant events and circumstances, such as macroeconomic conditions and the Company's overall financial performance to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company then evaluates how significant each of the identified factors could be to the fair value or carrying amount of a reporting unit and weighs these factors in totality in forming a conclusion whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, further goodwill impairment testing is not necessary. Otherwise, the Company would perform the first step of the two-step goodwill impairment test. As of October 1, 2011, and based on the Company's qualitative assessment, the Company determined that it was not more likely than not that the fair value was less than the carrying amount of each reporting unit and, therefore, the two-step goodwill impairment test was not necessary.

With respect to other indefinite-lived intangible assets, the Company determines the fair value of any indefinite-lived intangible asset using an income approach, compares the fair value to its carrying amount and records an impairment loss if the carrying amount exceeds its fair value. The Company uses the relief from royalty method to develop fair value estimates for trade names and trademarks. This method focuses on the level of royalty payments that the user of an intangible asset would be willing to pay for the use of the asset if it were not owned by the user. This method has been consistently applied between years. As of October 1, 2011, the Company determined that the fair values of trademarks, trade names, and in-process research and development exceeded their carrying amounts. For the nine months ended September 30, 2012, the Company recorded an impairment loss of $3,070 resulting in the elimination of in-process research & development (IPR&D) intangible assets related to a prior BioMedical segment acquisition. During the second quarter of 2012, higher forecasted costs and project delays represented impairment indicators requiring the Company to re-evaluate the fair value of the IPR&D intangible assets. The Company conducted an impairment test in accordance with Accounting Standards Codification (ASC) 350-30 "General Intangibles Other Than Goodwill" based on the multi-period excess earnings valuation method which determines fair value based on the present value of the prospective net cash flow attributable to the intangible asset. The Company determined that the fair value of the IPR&D intangible assets was zeroand impaired the intangible assets by a value equal to their carrying amount.

The following table displays the gross carrying amount and accumulated amortization for all intangible assets:

		September 30, 2012					December 31, 2011
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived assets:
Unpatented technology	9 years	$	41,461	$	(10,305	)	$	18,113	$	(9,024	)
Patents	10 years	8,980		(6,914		)	9,080		(5,434		)
Product names	14 years	9,281		(2,261		)	5,638		(1,818		)
Customer relations	13 years	165,192		(56,018		)	130,488		(48,840		)
		$	224,914	$	(75,498	)	$	163,319	$	(65,116	)
Indefinite-lived intangible assets:
Trademarks and trade names		$	45,215				$	39,280
In-process research and development		—					3,070
		$	45,215				$	42,350

The following table represents the changes in goodwill:

Balance as of January 1, 2012	$	288,770
Foreign currency adjustments	(177		)
Acquisition of AirSep Corporation	98,649
Balance as of September 30, 2012	$	387,242

Amortization expense for intangible assets subject to amortization was $3,810 and $3,342 for the three months ended September 30, 2012 and 2011, respectively, and $10,130 and $9,947 for the nine months ended September 30, 2012 and 2011. The Company estimates amortization expense to be recognized during the next five years as follows:

For the Year ending December 31,
2012	$	15,100
2013	18,900
2014	17,600
2015	15,900
2016	14,100

Share-based Compensation: The Company records share-based compensation to employees and directors, including grants of employee stock options, to be measured at fair value on the date of grant and expensed over the vesting period.

During the nine months ended September 30, 2012, the Company granted 104 stock options, 31 shares of restricted stock and stock unit awards, 15 performance stock units, and 18 leveraged restricted stock units. Non-employee directors received 4 stock awards with a fair value of $274. During the nine months ended September 30, 2012, participants in the Company's stock option plans exercised options to purchase 286 shares of the Company's common stock.

The stock options vest ratably over a four year period. Restricted stock and stock unit awards generally vest ratably over a three year period, and performance stock units and leveraged restricted stock units vest at the end of three years based on the achievement of certain performance and market conditions.

Share-based compensation expense was $1,530 and $1,407 for the three months ended September 30, 2012 and 2011, respectively, and $5,711 and $4,208 for nine months ended September 30, 2012 and 2011, respectively. As of September 30, 2012, the total share-based compensation expected to be recognized over the weighted average period of approximately 1.9 years is $8,075.

Convertible Debt: The Company determined that the embedded conversion feature within the Convertible Senior Subordinated Notes (the “Convertible Notes”) was clearly and closely related to the Company’s common stock and therefore exempt from separate accounting treatment under ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” Convertible Notes exempt from derivative accounting are recognized according to ASC 470-20, “Debt with Conversion and Other Options” by bifurcating the principal balance into a liability component and an equity component where the fair value of the liability component is estimated by calculating the present value of its cash flows discounted at an interest rate that the Company would have received for similar debt instruments that have no conversion rights (the “straight-debt rate”), and the equity component is the residual amount, net of tax, which creates a discount on the Convertible Notes. The Company recognizes non-cash interest accretion expense related to the carrying amount of the Convertible Notes which is accreted back to its principal amount over the expected life of the debt, which is also the stated life of the debt.

Recently Issued Accounting Pronouncements: In December 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-12, “Comprehensive Income – Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05 (Topic 220).” The amendments were made to allow the FASB time to consider whether there should be additional presentation and disclosure requirements for reclassifications out of accumulated other comprehensive income on the components of net income and other comprehensive income for all periods presented. All other requirements in ASU 2011-05 are not affected by this update. The adoption of this guidance did not have a material impact on the financial statements of the Company.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220).” The amendments in the ASU revise the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Topic 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. The amendments do not change the items that must be reported in other comprehensive income. The adoption of this guidance did not have a material impact on the financial statements of the Company since the amendments affect financial statement presentation only.

In May 2011, the FASB issued ASU 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (Topic 820).” The amendments in the ASU aim to align the principles for fair value measurements and the related disclosure requirements in accordance with U.S. GAAP and IFRS. This ASU mainly contains clarifications such as the specification that the "highest and best use" valuation concept for fair value measurements is relevant only when measuring the fair value of nonfinancial assets and is not relevant when measuring the fair value of financial assets or of liabilities. The ASU also requires new disclosures under U.S. GAAP such as quantitative information about the unobservable inputs used in a fair value measurement that is categorized within the Level 3 of the fair value hierarchy. The adoption of this guidance did not have a material impact on the Company’s financial position, results of operations or cash flows.

XML

Income Taxes (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Tax Expense (Benefit) [Abstract]
Liability for gross unrecognized tax benefits	$ 3,457		$ 3,457
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	968		968
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	1,921
Accrual for interest and penalties	114		114
Decrease in gross unrecognized tax benefits resulting from prior period tax positions			$ 905
Effective income tax rate	30.70%	28.90%	31.10%	30.80%
U.S. federal statutory income tax rate			35.00%

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2012

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed in the AirSep acquisition on August 30, 2012. The Company is in the process of obtaining third-party valuations and finalizing other analyses; thus, these provisional measurements are subject to change:

Net assets acquired:
Accounts receivable, net	$	24,280
Inventories, net	32,058
Prepaid expenses	586
Other current assets	3,837
Property, plant and equipment	5,370
Other assets	976
Accounts payable	(11,031		)
Customer advances and billings in excess of contract revenue	(4,782		)
Accrued salaries, wages and benefits	(1,837		)
Other current liabilities	(288		)
Current portion of warranty reserve	(9,920		)
Other long-term liabilities	(11,359		)
Net tangible assets acquired	27,890
Deferred income tax assets	13,051
Goodwill	98,649
Identifiable intangible assets	67,700
Long-term deferred tax liability	(24,840		)
Net assets acquired	$	182,450

XML

Employee Benefit Plans (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012 Plans	Sep. 30, 2011	Sep. 30, 2012 Plans	Sep. 30, 2011
Compensation and Retirement Disclosure [Abstract]
Number of frozen defined benefit plans	1		1
Components of net periodic pension expense:
Interest cost	$ 552	$ 603	$ 1,656	$ 1,809
Expected return on plan assets	(662)	(644)	(1,986)	(1,932)
Amortization of net loss	244	91	731	273
Total pension expense	$ 134	$ 50	$ 401	$ 150

XML

Reportable Segments (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Company’s reportable segments and its corporate headquarters is presented below:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	82,968	$	117,752	$	53,529	$	—		$	254,249
Operating income (loss)	17,057		19,948		7,051		(12,024		)	32,032

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	228,921	$	336,278	$	145,095	$	—		$	710,294
Operating income (loss)	44,785		54,447		25,498		(35,754		)	88,976

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	57,777	$	100,911	$	52,623	$	—		$	211,311
Operating income (loss)	12,584		16,109		8,548		(8,198		)	29,043

	Nine Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	149,414	$	275,966	$	149,570	$	—		$	574,950
Operating income (loss)	21,941		44,731		24,218		(26,051		)	64,839

	September 30, 2012		December 31, 2011
Assets:
Energy & Chemicals	$	237,381	$	203,067
Distribution & Storage	580,284		556,688
BioMedical	456,384		226,729
Corporate	49,187		187,991
Total Assets	$	1,323,236	$	1,174,475

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

The Company measures assets and liabilities at fair value on a recurring basis in three levels of input. The three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies, is:

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company is exposed to foreign currency exchange risk as a result of transactions in currencies other than the functional currency of certain subsidiaries. The Company utilizes foreign currency forward purchase and sale contracts to manage the volatility associated with foreign currency purchases and certain intercompany transactions in the normal course of business. Contracts typically have maturities of less than one year. Principal currencies include the euro, the British pound, the Czech koruna, the Japanese yen, and the Chinese yuan. The Company’s foreign currency forward contracts do not qualify as hedges as defined by accounting guidance. Changes in their fair value are recorded in the condensed consolidated statements of income and comprehensive income as foreign currency gains or losses. The changes in fair value generated net losses of $1,068 and $1,379 for the three months ended September 30, 2012 and 2011, respectively, and a net loss and a net gain of $1,619 and $1,943 for the nine months ended September 30, 2012 and 2011, respectively.

As of September 30, 2012, the Company held forward currency contracts to sell (in thousands): (i) 48,700 euros against the U.S. dollar, (ii) 2,280 euros against the Czech koruna, (iii) 800 Australian dollars against the U.S. dollar, (iv) 60,000 Japanese yen against the U.S. dollar, (v) 700 British pounds against the U.S. dollar, (vi) 510 British pounds against the Czech koruna, (vii) 980 U.S. dollars against the Czech koruna, and (viii) 200 British pounds against the euro. As of September 30, 2012, the fair value of the Company’s derivative assets and liabilities representing foreign currency forward contracts was $11 and $1,655, respectively, and were recorded in the condensed consolidated balance sheet as other current assets and liabilities.

As of December 31, 2011, the Company held forward currency contracts to buy 17,500 Czech koruna against the euro and to sell (i) 11,500 euros against the U.S. dollar, (ii) 4,700 Czech koruna against the U.S. Dollar, (iii) 130,000 Japanese yen against the U.S. dollar, (iv) 3,340 euros against the Czech koruna, (v) 3,000 Norwegian kroner against the euro, and (vi) 250 British pounds against the U.S. dollar. As of December 31, 2011, the fair value of the Company’s derivative assets and liabilities representing foreign currency forward contracts was $489 and $191, respectively. These were recorded in the condensed consolidated balance sheet as other current assets and liabilities. The Company’s foreign currency forward contracts are not exchange traded instruments and, accordingly, are classified as being valued using Level 2 inputs which are based on observable inputs such as quoted prices for similar assets and liabilities in active markets.

The Company does not enter into derivative instruments for trading or speculative purposes.

The fair value of the Company’s term loan portions of both the Restated Credit Facility (Term Loan) and the former Senior Credit Facility (as defined in Note C below) is estimated based on the present value of the underlying cash flows discounted using market interest rates. Under this method, the fair value of the Company’s Term Loan approximated its carrying amount as of September 30, 2012, and the fair value of the former Senior Credit Facility approximated its carrying amount as of December 31, 2011. The Company’s Term Loan and former Senior Credit Facility were valued using observable inputs and, accordingly, are classified as being valued using Level 2 inputs.

The fair value of the Convertible Notes exceeded its carrying amount by approximately 131% as of September 30, 2012 and approximately 108% as of December 31, 2011. The Convertible Notes are actively quoted instruments and, accordingly, are classified as being valued using Level 1 inputs. The fair value of the liability component of the Convertible Notes is based on the present value of its associated cash flows using a market interest rate for similar debt instruments without a conversion feature. The liability component of the Convertible Notes uses observable inputs other than quoted prices for similar liabilities in active markets and, accordingly, is classified as being valued using Level 2 inputs.

The estimated fair value of total contingent consideration relating to acquisitions in prior years as of September 30, 2012 and December 31, 2011 was $1,990 and $7,067, respectively, and was valued using a discounted cash flow approach, which includes assumptions for the probabilities of achieving gross sales or gross profit targets and the discount rate applied to the projected payments. The increase in fair value of total contingent consideration for the three months ended September 30, 2012 included increases of $73 and $15 related to prior BioMedical and Distribution & Storage acquisitions, respectively. The decrease in fair value of total contingent consideration for the nine months ended September 30, 2012 of $5,077 included a decrease of $4,236 related to a prior BioMedical acquisition offset by an increase of $459 related to a prior Distribution & Storage acquisition. There was also a $1,300 payment related to a prior Distribution & Storage acquisition during the nine months ended September 30, 2012. The majority of the decrease in fair value was caused by an adjustment to a contingent consideration obligation related to a prior BioMedical segment acquisition as a result of higher forecasted costs and delays of certain BioMedical projects. As noted in the Goodwill and Other Intangible Assets paragraph in Note A above, the Company determined that it would no longer meet the forecasted gross profit target required to satisfy its contingent consideration obligation. Therefore, the fair value of the contingent consideration obligation was determined to be zero.

The changes in fair value of contingent consideration were recorded as selling, general and administrative expenses in the condensed consolidated statements of income and comprehensive income. Based on achieving gross sales targets, the remaining maximum potential payout related to another prior BioMedical acquisition is $3,000. The valuation of contingent consideration is valued utilizing Level 3 inputs with reasonably available assumptions consistent with those made by other market participants.

XML

Condensed Consolidated Balance Sheets Parenthetical (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	30,000,390	29,612,684
Common stock, shares outstanding	30,000,390	29,612,684
Allowance for Doubtful Accounts Receivable, Current	$ 4,402	$ 2,360

XML

Basis of Preparation (Tables)

9 Months Ended

Sep. 30, 2012

Accounting Policies [Abstract]

Schedule of Inventory, Current

The components of inventory are as follows:

	September 30, 2012		December 31, 2011
Raw materials and supplies	$	84,686	$	64,832
Work in process	46,719		36,045
Finished goods	73,374		48,945
	$	204,779	$	149,822

Schedule of Product Warranty Liability

The changes in the Company’s consolidated warranty reserve during the three and nine months ended September 30, 2012 and 2011 are as follows (see Note G for further details on the acquired warranty reserves):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Beginning balance	$	11,248		$	12,849		$	13,181		$	13,372
Warranty expense	2,741			1,631			6,343			5,233
Warranty usage	(3,722		)	(1,949		)	(9,257		)	(6,074		)
Acquired warranty reserves	18,779			817			18,779			817
Ending balance	$	29,046		$	13,348		$	29,046		$	13,348

Schedule Of Finite Lived And Indefinite Lived Intangible Assets

The following table displays the gross carrying amount and accumulated amortization for all intangible assets:

		September 30, 2012					December 31, 2011
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived assets:
Unpatented technology	9 years	$	41,461	$	(10,305	)	$	18,113	$	(9,024	)
Patents	10 years	8,980		(6,914		)	9,080		(5,434		)
Product names	14 years	9,281		(2,261		)	5,638		(1,818		)
Customer relations	13 years	165,192		(56,018		)	130,488		(48,840		)
		$	224,914	$	(75,498	)	$	163,319	$	(65,116	)
Indefinite-lived intangible assets:
Trademarks and trade names		$	45,215				$	39,280
In-process research and development		—					3,070
		$	45,215				$	42,350

Schedule of Goodwill

The following table represents the changes in goodwill:

Balance as of January 1, 2012	$	288,770
Foreign currency adjustments	(177		)
Acquisition of AirSep Corporation	98,649
Balance as of September 30, 2012	$	387,242

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

The Company estimates amortization expense to be recognized during the next five years as follows:

For the Year ending December 31,
2012	$	15,100
2013	18,900
2014	17,600
2015	15,900
2016	14,100

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Nov. 01, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Entity Registrant Name	CHART INDUSTRIES INC
Entity Central Index Key	0000892553
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		30,015,307

XML

Debt and Credit Arrangements (Tables)

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Convertible Notes Payable Components

The following table represents the principal balance, the unamortized discount and the net carrying amount of the liability component and the carrying amount of the equity component of the Convertible Notes:

	September 30, 2012			December 31, 2011
Principal balance of liability component	$	250,000		$	250,000
Unamortized discount	(68,735		)	(75,526		)
Carrying amount of liability component	$	181,265		$	174,474
Equity component, net of deferred taxes	$	75,826		$	75,502

XML

Condensed Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Sales	$ 254,249	$ 211,311	$ 710,294	$ 574,950
Cost of sales	176,237	144,680	490,596	393,503
Gross profit	78,012	66,631	219,698	181,447
Selling, general and administrative expenses	42,170	34,127	117,522	105,326
Amortization expense	3,810	3,342	10,130	9,947
Impairment of intangible assets	0	0	3,070	0
Loss on disposal of assets	0	119	0	1,335
Operating expenses	45,980	37,588	130,722	116,608
Operating Income (Loss)	32,032	29,043	88,976	64,839
Other expenses (income):
Interest expense, net	4,006	6,361	11,657	14,358
Financing costs amortization	326	445	1,203	1,094
Foreign currency losses (gains)	461	(2,390)	1,879	(2,533)
Other nonoperating (income) expense	4,793	4,416	14,739	12,919
Income before income taxes	27,239	24,627	74,237	51,920
Income tax expense	8,354	7,122	23,064	15,992
Net income	18,885	17,505	51,173	35,928
Noncontrolling interest, net of tax	369	(35)	638	267
Net income attributable to Chart Industries, Inc.	18,516	17,540	50,535	35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$ 0.62	$ 0.60	$ 1.70	$ 1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$ 0.61	$ 0.59	$ 1.68	$ 1.19
Weighted average number of common shares outstanding – basic	29,839	29,288	29,743	29,088
Weighted average number of common shares outstanding – diluted	30,243	29,966	30,168	29,871
Comprehensive income, net of tax	21,428	6,459	52,537	32,292
Less: Comprehensive income (loss) attributable to noncontrolling interest, net of tax	369	(35)	638	267
Comprehensive income attributable to Chart Industries, Inc., net of tax	$ 21,059	$ 6,494	$ 51,899	$ 32,025

XML

Acquisitions

9 Months Ended

Sep. 30, 2012

Business Combinations [Abstract]

Acquisitions

Acquisitions

On August 30, 2012, the Company acquired 100% of the equity interests of AirSep Corporation (AirSep) for an aggregate cash purchase price of $182,450 (including approximately $2,800 in acquisition-related tax benefits acquired and $10,000 of debt which was retired upon completion of the acquisition). The fair value of the net assets acquired and goodwill at the date of acquisition were $83,801 and $98,649, respectively. The allocation of the purchase price was based on the fair value of assets acquired and liabilities assumed, and the related income tax impact of the acquisition adjustments. Goodwill was established due to the benefits that will be derived from the expansion of the Company's BioMedical segment oxygen concentrator business in the U.S. and Europe and growth potential for on-site air separation gas generation.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed in the AirSep acquisition on August 30, 2012. The Company is in the process of obtaining third-party valuations and finalizing other analyses; thus, these provisional measurements are subject to change:

Net assets acquired:
Accounts receivable, net	$	24,280
Inventories, net	32,058
Prepaid expenses	586
Other current assets	3,837
Property, plant and equipment	5,370
Other assets	976
Accounts payable	(11,031		)
Customer advances and billings in excess of contract revenue	(4,782		)
Accrued salaries, wages and benefits	(1,837		)
Other current liabilities	(288		)
Current portion of warranty reserve	(9,920		)
Other long-term liabilities	(11,359		)
Net tangible assets acquired	27,890
Deferred income tax assets	13,051
Goodwill	98,649
Identifiable intangible assets	67,700
Long-term deferred tax liability	(24,840		)
Net assets acquired	$	182,450

AirSep provides warranties on certain of its products, generally for periods of five years or less. The warranty reserve is calculated by considering historical warranty experience and specifically identified warranty issues. AirSep had experienced a significant number of warranty claims in one of its product lines. As of the acquisition date, the Company estimated the expected number of additional product returns based on historical returns experience for this product line. This was then extrapolated to estimate future returns for the remaining warranty periods. Expected future returns were multiplied by the estimated cost to replace the unit to establish a warranty reserve.

AirSep's identifiable intangible assets mainly include customer relationships and technology and is also comprised of trade names, trademarks, and backlog.

For the period August 31, 2012 through September 30, 2012, AirSep added $8,638 to sales. For the same period, the acquisition of AirSep also reduced operating income by $854 which included $608 of intangible asset amortization expense, $855 in amortization expense due to the write up of inventory to fair value, and $278 in management retention expenses. For the three and nine months ended September 30, 2012, the Company recognized $418 and $1,134 of AirSep acquisition related costs, respectively, that were expensed in the current year. These costs are included in the condensed consolidated statements of income and comprehensive income in selling, general and administrative expenses.

On August 1, 2011, Chart Germany GmbH, a wholly-owned subsidiary of the Company, completed the acquisition of 100% of the equity interests of GOFA Gocher Fahrzeugbau GmbH and related companies (GOFA) for a total purchase price of €26,261, net of cash acquired, including a final working capital adjustment of €947. The fair value of the net assets acquired and goodwill at the date of acquisition were $28,372 and $11,438, respectively. The allocation of the purchase price was based on the fair value of assets acquired and liabilities assumed, and the related income tax impact of the acquisition adjustments. Goodwill was established due to the benefits that will be derived from the expansion of the Company's LNG distribution product offering in Europe. GOFA, located in Goch, Germany, designs, manufactures, sells and services cryogenic and noncryogenic mobile equipment. GOFA results are included in the Company’s Distribution & Storage segment and added $13,946 and $2,608 in sales and operating income, respectively, during the nine months ended September 30, 2012.

On April 1, 2011, Chart Inc. completed the acquisition of 100% of the equity of Clever Fellows Innovation Consortium, Inc. (CFIC) for a total potential purchase price of $5,000 in cash, of which $2,000 has been paid. The remaining portion of the potential total purchase price represents contingent consideration to be paid over three years based on the attainment of certain revenue targets. The fair value of the net assets acquired and goodwill at the date of acquisition were $732 and $2,938, respectively. The goodwill was established due to the synergistic opportunities to enhance technology for cryogenic applications and grow sales in new product lines. CFIC is located in Troy, New York and develops and manufactures thermoacoustic technology products for cryogenic, heat transfer and related applications. CFIC's results are included in the Company’s BioMedical segment and added $1,198 in sales and reduced operating income by $1,561, during the nine months ended September 30, 2012.

Pro-forma information related to these acquisitions has not been presented because the impact on the Company’s consolidated results of operations is not material.

XML

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2012

Statement of Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss)

The following tables set forth the changes in accumulated other comprehensive income (loss) by component for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of July 1, 2012	$	10,969	$	(9,155	)	$	1,814
Other comprehensive income, net of tax	2,299		244			2,543
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Nine Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of January 1, 2012	$	12,635	$	(9,642	)	$	2,993
Other comprehensive income, net of tax	633		731			1,364
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Three Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of July 1, 2011	$	22,166		$	(4,945	)	$	17,221
Other comprehensive income (loss), net of tax	(11,137		)	91			(11,046		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

	Nine Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of January 1, 2011	$	14,938		$	(5,127	)	$	9,811
Other comprehensive income (loss), net of tax	(3,909		)	273			(3,636		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

XML

Employee Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2012

Compensation and Retirement Disclosure [Abstract]

Schedule of Net Periodic Pension Expense

The following table sets forth the components of net periodic pension expense for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Interest cost	$	552		$	603		$	1,656		$	1,809
Expected return on plan assets	(662		)	(644		)	(1,986		)	(1,932		)
Amortization of net loss	244			91			731			273
Total pension expense	$	134		$	50		$	401		$	150

XML

Restructuring Activities (Tables)

9 Months Ended

Sep. 30, 2012

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs

The following tables summarize the Company’s restructuring activities for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2012	$	—	$	6		$	225		$	—	$	231
Restructuring charges	—		—			359			—		359
Cash payments and other	—		(4		)	(329		)	—		(333		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2012	$	—	$	115		$	998		$	—	$	1,113
Restructuring charges	—		—			390			—		390
Cash payments and other	—		(113		)	(1,133		)	—		(1,246		)
Balance as of September 30, 2012	$	—	$	2		$	255		$	—	$	257

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of July 1, 2011	$	—	$	157		$	1,966		$	—	$	2,123
Restructuring charges	—		—			1,068			—		1,068
Cash payments and other	—		(43		)	(1,352		)	—		(1,395		)
Balance as of September 30, 2011	$	—	$	114		$	1,682		$	—	$	1,796

	Nine Months Ended September 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of January 1, 2011	$	103		$	388		$	2,088		$	—		$	2,579
Restructuring charges	—			26			4,528			437			4,991
Loss on disposal of assets	—			—			(1,216		)	—			(1,216		)
Cash payments and other	(103		)	(300		)	(3,718		)	(437		)	(4,558		)
Balance as of September 30, 2011	$	—		$	114		$	1,682		$	—		$	1,796

XML

Reportable Segments

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Reportable Segments

Reportable Segments

The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company's operating segments: Energy and Chemicals (E&C), Distribution and Storage (D&S) and BioMedical. The Company’s reportable segments are business units that are each managed separately because they manufacture, offer and distribute distinct products with different production processes and sales and marketing approaches. The E&C segment sells brazed aluminum and air-cooled heat exchangers, cold boxes and liquefied natural gas vacuum-insulated pipe to natural gas, petrochemical processing and industrial gas companies who use them for the liquefaction and separation of industrial and natural gases. The D&S segment sells cryogenic bulk storage systems, cryogenic packaged gas systems, cryogenic systems and components, beverage liquid CO₂ systems, cryogenic flow meter systems and cryogenic services to various companies for the storage and transportation of both industrial and natural gases. The BioMedical segment sells medical respiratory products, biological storage systems and other oxygen products. Due to the nature of the products that each segment sells, there are no intersegment sales. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and share-based compensation expenses that are not allocated to the reporting segments.

The Company evaluates performance and allocates resources based on operating income or loss from continuing operations before net interest expense, financing costs amortization expense, foreign currency gain or loss, income taxes and noncontrolling interest. The accounting policies of the reportable segments are the same as those described in Note A.

Information for the Company’s reportable segments and its corporate headquarters is presented below:

	Three Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	82,968	$	117,752	$	53,529	$	—		$	254,249
Operating income (loss)	17,057		19,948		7,051		(12,024		)	32,032

	Nine Months Ended September 30, 2012
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	228,921	$	336,278	$	145,095	$	—		$	710,294
Operating income (loss)	44,785		54,447		25,498		(35,754		)	88,976

	Three Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	57,777	$	100,911	$	52,623	$	—		$	211,311
Operating income (loss)	12,584		16,109		8,548		(8,198		)	29,043

	Nine Months Ended September 30, 2011
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales	$	149,414	$	275,966	$	149,570	$	—		$	574,950
Operating income (loss)	21,941		44,731		24,218		(26,051		)	64,839

	September 30, 2012		December 31, 2011
Assets:
Energy & Chemicals	$	237,381	$	203,067
Distribution & Storage	580,284		556,688
BioMedical	456,384		226,729
Corporate	49,187		187,991
Total Assets	$	1,323,236	$	1,174,475

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Tax Expense (Benefit) [Abstract]

Income Taxes

Income Taxes

The effective tax rate for the three and nine months ended September 30, 2012 of 30.7% and 31.1%, respectively, differs from the U.S. federal statutory rate of 35% primarily due to the effect of income earned by certain of the Company's foreign entities being taxed at lower rates than the federal statutory rate and the positive effect of the domestic production activities deduction. The effective tax rate for the three and nine months ended September 30, 2011 of 28.9% and 30.8%, respectively, differs from the federal statutory rate primarily due to the effect of income earned by certain of the Company’s foreign entities being taxed at lower rates than the U.S. federal statutory rate and the positive effect of the domestic production activities deduction.

As of September 30, 2012, the Company has recorded a $3,457 liability, in accordance with ASC 740-10-25 “Income Taxes,” for gross unrecognized tax benefits. This amount includes $968 of unrecognized tax benefits which, if ultimately recognized, will reduce the Company's annual effective tax rate. During the third quarter of 2012, gross unrecognized tax benefits increased $1,921 due to tax positions taken on prior year returns. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2012, the Company had accrued approximately $114 for the payment of interest and penalties. During the first quarter of 2012, the Internal Revenue Service (IRS) completed an examination of the Company's amended U.S. income tax returns for 2005 and 2006. As a result of the completion of the examination, the Company's gross unrecognized tax benefits decreased by $905.

XML

Employee Benefit Plans

9 Months Ended

Sep. 30, 2012

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans

Employee Benefit Plans

The Company has one defined benefit pension plan which is frozen that covers certain U.S. hourly and salaried employees. The defined benefit plan provides benefits based primarily on the participants’ years of service and compensation.

The following table sets forth the components of net periodic pension expense for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Interest cost	$	552		$	603		$	1,656		$	1,809
Expected return on plan assets	(662		)	(644		)	(1,986		)	(1,932		)
Amortization of net loss	244			91			731			273
Total pension expense	$	134		$	50		$	401		$	150

XML

Basis of Preparation (Policies)

9 Months Ended

Sep. 30, 2012

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation: The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation. Investments in affiliates where the Company’s ownership is between 20 percent and 50 percent, or where the Company does not have control, but has the ability to exercise significant influence over operations or financial policy, are accounted for under the equity method.

Use of Estimates

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cost of Sales

Cost of Sales: Manufacturing expenses associated with sales are included in cost of sales. Cost of sales includes all materials, direct and indirect labor, inbound freight, purchasing and receiving, inspection, internal transfers and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs, manufacturing engineering, project management and depreciation expense for assets used in the manufacturing process are included in cost of sales.

Selling, general and administrative costs

Selling, General and Administrative Costs (SG&A): SG&A includes selling, marketing, customer service, product management, design engineering, and other administrative costs not directly supporting the manufacturing process as well as depreciation and amortization expense associated with non-manufacturing assets. In addition, SG&A includes corporate operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and share-based compensation expense.

Cash and Cash Equivalents

Cash and Cash Equivalents: The Company considers all investments with an initial maturity of three months or less when purchased to be cash equivalents. The December 31, 2011 balances include money market investments, certificates of deposit, and commercial paper. As of September 30, 2012, Chart Cryogenic Distribution Equipment (Changzhou) Company Limited, a joint venture of the Company, and Chart Cryogenic Engineering Systems (Changzhou) Company Limited held $1,055 and $844 in restricted cash on deposit, respectively, to cover guarantees.

Short-Term Investments

Short-Term Investments: From time to time, the Company invests in short-term, highly liquid, variable rate instruments, which have stated maturities of greater than three months but less than six months. These short-term investments are recorded at cost which approximates fair value. The Company has determined that its investment securities are available and intended for use in current operations and, accordingly, classifies investment securities as current assets. There were no short term investments at September 30, 2012 or December 31, 2011.

Inventories

Inventories: Inventories are stated at the lower of cost or market with cost being determined by the first-in, first-out (“FIFO”) method.

Revenue Recognition

Revenue Recognition: For the majority of the Company’s products, revenue is recognized when products are shipped, title has transferred and collection is reasonably assured. For these products, there is also persuasive evidence of an arrangement and the selling price to the buyer is fixed or determinable. For brazed aluminum heat exchangers, cold boxes, liquefied natural gas fueling stations and engineered tanks, the Company uses the percentage of completion method of accounting. Earned revenue is based on the percentage of incurred costs to date compared to total estimated costs at completion after giving effect to the most current estimates. The cumulative impact of revisions in total cost estimates during the progress of work is reflected in the period in which these changes become known. Earned revenue reflects the original contract price adjusted for agreed upon claims and change orders, if any. Losses expected to be incurred on contracts in process, after consideration of estimated minimum recoveries from claims and change orders, are charged to operations as soon as such losses are known. Pre-contract costs relate primarily to salaries and benefits incurred to support the selling effort and are expensed as incurred. Change orders resulting in additional revenue and profit are recognized upon approval by the customer based on the percentage of incurred costs to date compared to total estimated costs at completion. Certain contracts include incentive-fee arrangements. The incentive fees in such contracts can be based on a variety of factors but the most common are the achievement of target completion dates, target costs, and/or other performance criteria. Incentive-fee revenue is not recognized until it is earned. Timing of amounts billed on contracts varies from contract to contract and could cause a significant variation in working capital requirements. The Company reports sales net of tax assessed by qualifying governmental authorities.

Product Warranties

Product Warranties: The Company provides product warranties with varying terms and durations for the majority of its products. The Company calculates its warranty reserve by considering historical warranty experience and specifically identified warranty issues. The Company records warranty expense in cost of sales. Product warranty claims not expected to occur within one year are recorded in other long-term liabilities in the condensed consolidated balance sheets. Actual experience could differ from the amounts estimated requiring adjustments to the liability in future periods.

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets: The Company does not amortize goodwill or other indefinite-lived intangible assets, but reviews them at least annually for impairment, and on an interim basis if necessary, using a measurement date of October 1st. The Company amortizes intangible assets that have finite lives over their useful lives.

With respect to goodwill, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The reporting units are the same as our operating segments, which are also the reportable segments: Energy & Chemicals, Distribution & Storage, and BioMedical. The Company first evaluates relevant events and circumstances, such as macroeconomic conditions and the Company's overall financial performance to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company then evaluates how significant each of the identified factors could be to the fair value or carrying amount of a reporting unit and weighs these factors in totality in forming a conclusion whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, further goodwill impairment testing is not necessary. Otherwise, the Company would perform the first step of the two-step goodwill impairment test. As of October 1, 2011, and based on the Company's qualitative assessment, the Company determined that it was not more likely than not that the fair value was less than the carrying amount of each reporting unit and, therefore, the two-step goodwill impairment test was not necessary.

With respect to other indefinite-lived intangible assets, the Company determines the fair value of any indefinite-lived intangible asset using an income approach, compares the fair value to its carrying amount and records an impairment loss if the carrying amount exceeds its fair value. The Company uses the relief from royalty method to develop fair value estimates for trade names and trademarks. This method focuses on the level of royalty payments that the user of an intangible asset would be willing to pay for the use of the asset if it were not owned by the user. This method has been consistently applied between years.

Stock-based Compensation

Share-based Compensation: The Company records share-based compensation to employees and directors, including grants of employee stock options, to be measured at fair value on the date of grant and expensed over the vesting period.

During the nine months ended September 30, 2012, the Company granted 104 stock options, 31 shares of restricted stock and stock unit awards, 15 performance stock units, and 18 leveraged restricted stock units. Non-employee directors received 4 stock awards with a fair value of $274. During the nine months ended September 30, 2012, participants in the Company's stock option plans exercised options to purchase 286 shares of the Company's common stock.

The stock options vest ratably over a four year period. Restricted stock and stock unit awards generally vest ratably over a three year period, and performance stock units and leveraged restricted stock units vest at the end of three years based on the achievement of certain performance and market conditions.

Convertible Debt

Convertible Debt: The Company determined that the embedded conversion feature within the Convertible Senior Subordinated Notes (the “Convertible Notes”) was clearly and closely related to the Company’s common stock and therefore exempt from separate accounting treatment under ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” Convertible Notes exempt from derivative accounting are recognized according to ASC 470-20, “Debt with Conversion and Other Options” by bifurcating the principal balance into a liability component and an equity component where the fair value of the liability component is estimated by calculating the present value of its cash flows discounted at an interest rate that the Company would have received for similar debt instruments that have no conversion rights (the “straight-debt rate”), and the equity component is the residual amount, net of tax, which creates a discount on the Convertible Notes. The Company recognizes non-cash interest accretion expense related to the carrying amount of the Convertible Notes which is accreted back to its principal amount over the expected life of the debt, which is also the stated life of the debt.

XML

Acquisitions (Details) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended		1 Months Ended			9 Months Ended			9 Months Ended		1 Months Ended
	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 BioMedical [Member] USD ($)	Sep. 30, 2011 BioMedical [Member] USD ($)	Sep. 30, 2012 BioMedical [Member] USD ($)	Sep. 30, 2011 BioMedical [Member] USD ($)	Sep. 30, 2012 AirSep [Member] USD ($)	Sep. 30, 2012 AirSep [Member] USD ($)	Aug. 30, 2012 AirSep [Member] USD ($)	Sep. 30, 2012 AirSep [Member] BioMedical [Member] USD ($)	Aug. 01, 2011 GOFA [Member] USD ($)	Aug. 01, 2011 GOFA [Member] EUR (€)	Sep. 30, 2012 GOFA [Member] Distribution and Storage Segment [Domain] USD ($)	Sep. 30, 2012 Clever Fellows Innovation Consortium [Member]	Apr. 02, 2011 Clever Fellows Innovation Consortium [Member] USD ($)	Sep. 30, 2012 Clever Fellows Innovation Consortium [Member] BioMedical [Member] USD ($)	Aug. 30, 2012 Maximum [Member] AirSep [Member] USD ($)	Sep. 30, 2012 Selling, General and Administrative Expenses [Member] AirSep [Member] BioMedical [Member] USD ($)
Business Acquisition [Line Items]
Business combination equity interest percentage											100.00%		100.00%	100.00%			100.00%
Working capital adjustment														€ 947
Fair value of net assets aquired											83,801		28,372				732
Operating Income (Loss)	32,032	29,043	88,976	64,839	7,051	8,548	25,498	24,218				(854)			2,608			(1,561)
Amortization expense	3,810	3,342	10,130	9,947								608
Business Acquisition, Amortization of Stepped Up Inventory Basis												855
Management Retention Expense																				278
Business Combination, Acquisition Related Costs									418	1,134
Net assets acquired:
Accounts receivable, net											24,280
Inventories, net											32,058
Prepaid expenses											586
Other current assets											3,837
Property, plant and equipment											5,370
Other assets											976
Accounts payable											(11,031)
Customer advances and billings in excess of contract revenue											(4,782)
Accrued salaries, wages and benefits											(1,837)
Other current liabilities											(288)
Current portion of warranty reserve											(9,920)
Other long-term liabilities											(11,359)
Net tangible assets acquired											27,890
Deferred income tax assets											13,051
Goodwill											98,649		11,438				2,938
Identifiable intangible assets											67,700
Long-term deferred tax liability											(24,840)
Net assets acquired											182,450
Total purchase price														26,261
Business Acquisition, Purchase Price Allocation, Income Taxes Receivable											2,800
Business Acquisition, Purchase Price Allocation, Liabilities Assumed																			10,000
Potential purchase price																	5,000
Cash paid for acquistion																	2,000
Duration for payments of contingent consideration																3 years
Sales	$ 254,249	$ 211,311	$ 710,294	$ 574,950								$ 8,638			$ 13,946			$ 1,198

XML

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2012

Statement of Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

	Three Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of July 1, 2012	$	10,969	$	(9,155	)	$	1,814
Other comprehensive income, net of tax	2,299		244			2,543
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Nine Months Ended September 30, 2012
	Foreign currency translation adjustments		Pension liability adjustments, net of taxes			Accumulated other comprehensive income
Balance as of January 1, 2012	$	12,635	$	(9,642	)	$	2,993
Other comprehensive income, net of tax	633		731			1,364
Balance as of September 30, 2012	$	13,268	$	(8,911	)	$	4,357

	Three Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of July 1, 2011	$	22,166		$	(4,945	)	$	17,221
Other comprehensive income (loss), net of tax	(11,137		)	91			(11,046		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

	Nine Months Ended September 30, 2011
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive income (loss)
Balance as of January 1, 2011	$	14,938		$	(5,127	)	$	9,811
Other comprehensive income (loss), net of tax	(3,909		)	273			(3,636		)
Balance as of September 30, 2011	$	11,029		$	(4,854	)	$	6,175

XML

Basis of Preparation - Cash and Cash Equivalents (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012
Chart Cryogenic Distribution Equipment Co. Ltd. [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash on deposit	$ 1,055
Chart Cryogenic Engineering Systems Co., Ltd. [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash on deposit	$ 844

XML

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
OPERATING ACTIVITIES
Net income	$ 51,173	$ 35,928
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,771	20,410
Interest accretion of convertible notes discount	6,764	1,421
Employee share-based compensation expense	5,711	4,208
Financing costs amortization	1,203	1,094
Foreign Currency Transaction Gain (Loss), Unrealized	(3,095)	1,559
Loss on disposal of assets	0	1,335
Impairment of intangible assets	3,070	0
Reversal of contingent consideration liability	(4,620)	0
Other non-cash operating activities	(609)	(1,826)
(Decrease) increase in cash resulting from changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(28,417)	(23,358)
Inventory	(22,594)	(21,283)
Unbilled contract revenues and other current assets	(3,882)	(10,244)
Accounts payable and other current liabilities	(18,134)	6,312
Customer advances and billings in excess of contract revenue	(1,058)	24,605
Net Cash Provided By Operating Activities	14,473	37,043
INVESTING ACTIVITIES
Payments to Acquire Productive Assets	(28,951)	(15,161)
Proceeds from Sales of Assets, Investing Activities	2,040	0
Acquisition of businesses, net of cash acquired	(182,450)	(37,680)
Other investing activities	(359)	388
Net Cash Used In Investing Activities	(209,720)	(52,453)
FINANCING ACTIVITIES
Proceeds from long-term debt	21,375	0
Borrowings on revolving credit facilities	18,387	0
Principal payments on long-term debt	(3,500)	(4,875)
Proceeds from issuance of convertible notes	0	250,000
Proceeds from issuance of warrants	0	48,848
Payment for call options related to convertible notes	0	(66,486)
Payment of deferred financing costs	(1,445)	(7,340)
Proceeds from exercise of options	3,324	5,101
Excess Tax Benefit (Tax Deficiency) from Share-based Compensation, Financing Activities	7,934	6,984
Payment of contingent consideration	1,300	1,300
Common stock repurchases	(4,537)	(1,090)
Net Cash Provided By Financing Activities	40,238	229,842
Effect of exchange rate changes on cash	3,923	2,501
Net (decrease) increase in cash and cash equivalents	(151,086)	216,933
Cash and cash equivalents at beginning of period	256,861	165,112
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 105,775	$ 382,045

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

The following table presents calculations of net income per share of common stock for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Net income attributable to Chart Industries, Inc.	$	18,516	$	17,540	$	50,535	$	35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$	0.62	$	0.60	$	1.70	$	1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$	0.61	$	0.59	$	1.68	$	1.19
Weighted average number of common shares outstanding – basic	29,839		29,288		29,743		29,088
Dilutive effect of share-based awards	391		678		412		783
Dilutive effect of convertible debt	13		—		13		—
Weighted average number of common shares outstanding – diluted	30,243		29,966		30,168		29,871

Certain common shares that may be issuable upon the vesting of share-based awards and potential settlements under convertible note hedge and capped call transactions used to offset the dilutive effect of the Convertible Notes were not included in the computation of diluted earnings per share as they were anti-dilutive. There were 116 and 110 anti-dilutive shares for the three and nine months ended September 30, 2012, respectively, and 148 and 97 anti-dilutive shares for the three and nine months ended September 30, 2011, respectively.

XML

Basis of Preparation - Goodwill and Other Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 0	$ 0	$ 3,070	$ 0
Amortization expense	3,810	3,342	10,130	9,947
Gross carrying amount, finite-lived assets	224,914		224,914		163,319
Accumulated amortization, finite-lived assets	(75,498)		(75,498)		(65,116)
Indefinite-lived intangible assets	45,215		45,215		42,350
Changes in goodwill:
Balance as of January 1, 2012			288,770
Foreign currency adjustments			(177)
Balance as of September 30, 2012	387,242		387,242
For the Year ending December 31,
2012	15,100		15,100
2013	18,900		18,900
2014	17,600		17,600
2015	15,900		15,900
2016	14,100		14,100
Trademarks and trade names [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	45,215		45,215		39,280
In-process research and development [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	0		0		3,070
Unpatented technology [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangilbe assets (in year)			9 years
Gross carrying amount, finite-lived assets	41,461		41,461		18,113
Accumulated amortization, finite-lived assets	(10,305)		(10,305)		(9,024)
Patents [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangilbe assets (in year)			10 years
Gross carrying amount, finite-lived assets	8,980		8,980		9,080
Accumulated amortization, finite-lived assets	(6,914)		(6,914)		(5,434)
Product names [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangilbe assets (in year)			14 years
Gross carrying amount, finite-lived assets	9,281		9,281		5,638
Accumulated amortization, finite-lived assets	(2,261)		(2,261)		(1,818)
Customer relations [Member]
Schedule of Finite-lived and Indefinite-lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangilbe assets (in year)			13 years
Gross carrying amount, finite-lived assets	165,192		165,192		130,488
Accumulated amortization, finite-lived assets	$ (56,018)		$ (56,018)		$ (48,840)

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table presents calculations of net income per share of common stock for the three and nine months ended September 30, 2012 and 2011:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Net income attributable to Chart Industries, Inc.	$	18,516	$	17,540	$	50,535	$	35,661
Net income attributable to Chart Industries, Inc. per common share – basic	$	0.62	$	0.60	$	1.70	$	1.23
Net income attributable to Chart Industries, Inc. per common share – diluted	$	0.61	$	0.59	$	1.68	$	1.19
Weighted average number of common shares outstanding – basic	29,839		29,288		29,743		29,088
Dilutive effect of share-based awards	391		678		412		783
Dilutive effect of convertible debt	13		—		13		—
Weighted average number of common shares outstanding – diluted	30,243		29,966		30,168		29,871